Biallelic variants in *ARHGAP19* cause a motor-predominant neuropathy with asymmetry and conduction slowing

3	Natalia	Dominik ^{1#} , Stephanie Efthymiou ^{1#§} , Christopher J. Record ¹ , Xinyu Miao ² , Renee Lin ¹ , Jevin												
4	Parma	r ³ , Annarita Scardamaglia ¹ , Reza Maroofian ¹ , Gabriel Aughey ⁴ , Abigail Wilson ⁴ , Simon Lowe ⁴ ,												
5	Riccard	lo Curro ¹ , Ricardo P. Schnekenberg ¹ , Shahryar Alavi ¹ , Leif Leclaire ² , Yi He ² , Kristina												
6	Zhelchenska ¹ , Yohanns Bellaiche ⁵ , Isabelle Gaugué ⁵ , Mariola Skorupinska ¹ , Liedewei Van de													
7	Vondel ^{6,7} , Sahar I. Da'as ⁸ , Valentina Turchetti ¹ , Serdal Güngör ⁹ , Ehsan Ghayoor Karimiani ^{10,11} , Camila													
8	Armirola Ricaurte ^{12,13} , Haluk Topaloglu ¹⁴ , Albena Jordanova ^{12,13,15} , Mashaya Zaman ¹⁶ , Selina H.													
9	Banu ¹⁶	. Wilson Margues ¹⁷ . Pedro José Tomaselli ¹⁸ . Busra Avnekin ¹ . Ali Cansu ¹⁹ . Husevin Per ²⁰ . Avten												
10	Gülec ²⁰	$^{\circ}$ Javeria Raza Alvi ²¹ Tinu Sultan ²¹ Arif Khan ^{22,23} Giovanni Zifarelli ²⁴ Shahnaz Ibrahim ²⁵ Grazia												
11	MSM	$(ancini^{26} \text{ M} \text{ Mahdi Motazacker}^{27} \text{ Esther Brusse}^{26} \text{ Vincenzo Luno}^{28} \text{ Teresa Sevilla}^{29,30} A Nazlu$												
12	Bacak ^{3:}	1 Sevma Tekgul ³¹ Robin Palvadeau ³¹ Jonathan Baets ^{6,7,32} Vesim Parman ³³ Arman Cakar ³³												
12	Daşak Dita Ua	3333 333												
10		n Valling, Toblas B. Hadek , Jail-Hendik Stalling, Katilin Grunullahi-Hauser,												
14 1 E	Joonyu	ni Park (1977), Stephan Zuchner (1977), Niger G. Lang, Linusay Wilson , Alexander M.Rosson ,												
15	James	Poike ¹⁰ , Fernanda Barbosa Figueiredo ¹¹ , Andre Luiz Pessoa ¹⁴ , Fernando Kok ¹¹ , Antonio												
10	Roarig	ues Coimbra-Ineto", Marcondes C. França Jr", Yalda Jamshidi", Glanina Ravenscroft", Sherifa												
1/	Anmed	I Hamed ^{**} , Wendy K. Chung ^{**} , Daniel P. Osborn ^{**} , Michael Hanna ⁺ , Andrea Cortese ⁺ , Mary M.												
18	Reilly ¹	, James E. C. Jepson ⁴ , Nathalie Lamarche-Vane ^{2,31} , Henry Houlden ¹												
19														
20	1.	Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology, London,												
21		WC1N 3BG, UK.												
22	2.	Department of Anatomy and Cell Biology, McGill University, Montréal, QC H3A 0C7, Canada.												
23	3.	Harry Perkins Institute of Medical Research, Centre for Medical Research, University of												
24		Western Australia, Perth, Western Australia, Australia.												
25	4.	Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology,												
26		London, UK.												
27	5.	Team "Polarity Division and Morphogenesis" INSTITUT CURIE, France.												
28	6.	Translational Neurosciences, Faculty of Medicine and Health Sciences, University of												
29		Antwerp, Antwerp, Belgium.												
30	7.	Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp,												
31		Antwerp, Belgium.												
32	8.	Department of Human Genetics, Sidra Medicine, Doha, Qatar.												
33	9.	Inonu University, Faculty of Medicine, Turgut Ozal Research Center, Department of Pediatric												
34		Neurology, Malatya, Turkey.												
35	10	. Department of Molecular Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.												
36	11.	. Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer												
37		Terrace, London, SW17 ORE, UK.												
38	12.	Molecular Neurogenomics group, VIB Center for Molecular Neurology, VIB, Antwerp,												
39		Belgium.												
40	13.	Molecular Neurogenomics group, Department of Biomedical Sciences, University of												
41		Antwerp, Antwerp, Belgium.												
42	14.	Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.												
43	15.	Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 1431, Sofia,												
44		Bulgaria.												
45	16	Department of Pediatric Neurology, Dr. M.R. Khan Shishu (Children) Hospital and ICH.												
46		Mirpur, Dhaka, Bangladesh.												
47	17	Department of Neurosciences, School of Medicine of Ribeirão Preto. University of São Paulo.												
48	_,	São Paulo, Brazil.												
49	18	Clinical Hospital of Ribeirão Preto. Department of Neurosciences and Behaviour Sciences												
50		University of São Paulo, Ribeirão Preto, Brazil												
	NOTE: T	nis preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.												

51 2	19.	Department of Pediatric Neurology, Faculty of Medicine, Farabi Hospital, Karadeniz
52	~~	Technical University, Trabzon, Turkey.
53 2	20.	Department of Pediatric Neurology, Erciyes University, Kayseri, Turkey.
54 2	21.	Children's Hospital & the Institute of Child Health, Lahore, Pakistan.
55 2	22.	Pediatric Neurology, Neuropedia Hospital, Dubai, ARE.
56 2	23.	Pediatric Neurology, Mohammed Bin Rashid University of Medicine and Health Sciences,
57		Dubai, ARE.
58 2	24.	CENTOGENE GmbH, Am Strande 7, 18055 Rostock, Germany.
59 2	25.	Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
60 2	26.	Department of Clinical Genetics, ErasmusMC University Medical Center, Dr.Molewaterplein
61		40, 3015GD Rotterdam, The Netherlands.
62 2	27.	Laboratory of Genome Diagnostics, Department of Human Genetics, Amsterdam UMC,
63		University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
64 2	28.	Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF),
65		46012 Valencia, Spain.
66 2	29.	Hospital Universitari i Politècnic La Fe & IIS La Fe, Neuromuscular Diseases Unit, Department
67		of Neurology, Valencia, Spain.
68 3	30.	Universitat de València, Valencia, Spain. Centro de Investigación Biomédica en Red de
69		Enfermedades Raras (CIBERER), Spain.
70 3	31.	Suna and İnan Kırac Foundation. Neurodegeneration Research Laboratory (NDAL). Research
71		Center for Translational Medicine (KUTTAM). Koc University School of Medicine. Istanbul.
72		Turkey.
73 3	32.	Neurophysical Neur
74		Antwern Belgium
75 3	22	Department of Neurology Istanbul Medical School Istanbul University Istanbul Turkey
76	33. 34	Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge
70		Cambridge Biomedical Campus Cambridge LIK
78 3	25	Denartment of Clinical Neurosciences, John Van Geest Centre for Brain Renair, School of
70 .	55.	Clinical Medicine University of Cambridge Cambridge LIK
80 3	26	Center for Bare Disease University of Tübingen Tübingen Germany
81 S	30. 27	Institute of Medical Genetics and Applied Genomics. University of Tübingen, Tübingen
87	57.	Germany
02 92 :	20	Denartment of Enilentology Center of Neurology University of Tübingen, Germany
8J 3	20.	Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
	39. 40	John D. Hussman Institute for Human Conomics, University of Miami, Miami, El, USA
oc /	40. 41	Dr. John T. Masdanald Equidation Department of Human Constics. University of Miami
00 ⁴	+ Ι.	Miami, EL USA
0/	17	Wildilli, FL, USA.
80 4	42.	Centre for Neuroinuscular Diseases, Department of Neuroinuscular Diseases, OCL Queen
89	40	Square institute of Neurology, London, OK.
90 2	43.	Neurogenetics Laboratory, The National Hospital for Neurology and Neurosurgery and the
91		North Thames Genomics Laboratory Hub, London, UK.
92 2	44.	Mendelics Genomic Analysis, Sao Paulo, SP, Brazil.
93 4	45.	Universidade Federal Do Ceara - UFC and Hospital Infantil Albert Sabin, Fortaleza, Brazil.
94 4	46.	Department of Neurology, School of Medical Sciences, University of Campinas (UNICAMP),
95	. –	Campinas, SP, Brazil.
96 4	47.	iviolecular and Clinical Sciences Institute, St. George's, University of London, SW17 ORE, UK.
9/ 4	48.	Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut,
98		Egypt.
99 4	49.	Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA,
100		USA.

50. Genetics Sections, Molecular and Clinical Sciences Institute, St George's University of London, Cranmer Terrace, London, SW17 ORE, UK.

- 103 51. Cancer Research Program, Research Institute of the McGill University Health Centre,
 104 Montréal, QC H4A 3J1, Canada.
- 105

106 #Contributed equally

- 107 §Correspondence to Dr. Stephanie Efthymiou, Department of Neuromuscular Disorders, UCL Queen
- 108 Square Institute of Neurology, UCL, London, WC1N 3BG, UK, s.efthymiou@ucl.ac.uk

109 Abstract

- 110 Charcot-Marie-Tooth Disease is a clinically and genetically heterogeneous group of hereditary
- 111 neuropathies, with over 100 causative genes identified to date. Despite progress in genetic
- sequencing, around a quarter of patients remain unsolved. Through international collaborations, we
- identified 16 recessive variants in Rho GTPase activating protein 19 (ARHGAP19) causing motor-
- 114 predominant neuropathy with conduction slowing in 25 individuals from 20 unrelated multi-ancestry
- 115 families. ARHGAP19 is a GTPase-activating protein with activity towards RhoA. *In vitro* biochemical
- assays revealed that variants located within the GAP domain cause loss of GAP activity. iPSc-derived
- 117 motor neurons exhibited 50% knockdown of ARHGAP19 protein. In vivo genetic perturbations of the
- 118 Drosophila melanogaster ARHGAP19 ortholog RhoGAP54D reduced self-driven locomotor activity
- and startle responses to visual stimuli. Zebrafish loss-of-function models similarly exhibited

120 movement deficits, coupled with increased motor neuron axonal branching but shorter caudal

121 primary motor neurons. Together, these findings establish ARHGAP19 as a novel cause of early-

- 122 onset neuropathy through a loss-of-function mechanism.
- 123

125

- 124 Keywords: neuropathy, Charcot–Marie–Tooth, Rho/ROCK pathway, next generation sequencing
- 126 **Running title:** *ARHGAP19* cause a motor-predominant neuropathy
- 127 Number of figures: 7
- 128 Number of tables: 1
- 129 Number of supplementary items: 14 (9 Tables, 5 Figures)
- 130

131 Introduction

- 132 Charcot-Marie-Tooth disease (CMT), also called hereditary motor and sensory neuropathy (HMSN) is
- 133 the most prevalent Mendelian inherited neuropathy. Notably, inherited peripheral neuropathies are
- amongst the most frequently inherited neurologic diseases. The prevalence of CMT varies amongstpopulations but is estimated at around 1 in 2,500 individuals (1).
- 135 populations but is estimated at around 1 in 2,500 individuals (1).
- Patients with CMT can range from mildly affected to severely disabled and the disease presents with
- progressive weakness and atrophy of muscles, especially in distal limbs. Often foot abnormalities
- such as *pes cavus* or hammer toes may be associated with the disease. Symptoms of CMT overlap
- between neuropathies and subtypes of CMT. Despite many genes being associated to inherited
- 140 CMT, there remains a large proportion of genetically unexplained cases. However, family history,
- 141 nerve conduction studies and thorough clinical evaluation can aid differential diagnosis (2).
- 142
- 143 The Rho family of small GTPases is composed of 20 members that include RhoA, Rac1, and CDC42.
- 144 Rho GTPases act as molecular switches by cycling between inactive guanine nucleotide diphosphate
- (GDP) bound state and active, triphosphate (GTP) bound state and are involved in signalling
- pathways that control actin cytoskeleton reorganisation, cell adhesion, migration, and cell division.
- 147 The activity of Rho GTPases is tightly regulated by three classes of proteins, Guanine nucleotide
- 148 Exchange Factors (GEFs) which facilitate the exchange from GDP to GTP; GTPase-Activating Proteins
- 149 (GAPs) which stimulate the intrinsic GTPase activity, resulting in hydrolysis of GTP and protein
- 150 inactivation; and Guanine Nucleotide Dissociation Inhibitors (GDIs) which sequester and maintain

151 Rho GTPases inactive in the cytoplasm(3) (4). In humans, over 66 RhoGAPs and 80 RhoGEFs have

been identified for 20 members of Rho family that they can act on, and many are implicated in 152

neurological diseases, including CMT (4). For example, PLEKHG5, a GEF gene that regulates 153

154 autophagy of synaptic vesicles in axonal terminals, is associated with CMT (5). Furthermore, variants

- 155 in MYO9B, a RhoGAP gene, have recently been shown to cause CMT type 2 (CMT2) and optic
- 156 atrophy. Whether CMT can be caused by mutations in other regulators of Rho GTPases, however, 157 remains an open question.
- 158

159 Here, we report the clinical phenotypes associated with biallelic, autosomal recessive variants in

160 ARHGAP19 in 25 individuals with CMT from 20 families. ARHGAP19 is a small, 494 amino acid (AA)

161 RhoGAP protein, displaying GAP activity towards RhoA but not Rac1 and Cdc42, thus acting as a 162 negative regulator of the RhoA/ Rho-associated kinase (ROCK) pathway. ARHGAP19 has previously

been shown to have an essential role in T-lymphocyte cytokinesis and phosphorylation by kinases 163

such as ROCK at Ser422 and CDK1 at Thr404 and Thr476 is essential for its role in the control of cell 164

165 division (3, 6). We provide mechanistic evidence for the contribution of variants to CMT suggesting a

166 loss of function (LOF) mechanism through the use of individual patient cell lines, in vitro GAP assay,

in vivo Drosophila melanogaster and Danio rerio knockdown models as well as in-silico molecular 167

168 modelling. Both Drosophila and zebrafish LOF models exhibit significant motor defects, while

169 zebrafish model indicates an impact of ARHGAP19 LOF on motoneuron length and branching.

170 171 **Methods**

172 **Study Participants**

173 Individuals were recruited via an international collaborative network of research and diagnostic 174 sequencing laboratories. Samples and clinical information were obtained, with informed consent,

175 from each institution using local institutional review board (IRB) ethics for functional analysis of

176 human DNA, fibroblasts and biomaterial. Clinical data collection involved a detailed review of

177 medical records, photographs, videos, and phone interviews, as well as a clinical re-evaluation of

178 nerve conduction studies by a neurologist. GeneMatcher and RD-Connect (GPAP) platform facilitated

179 the identification of additional patients. Table 1 and Supplementary table 1 summarize the clinical

180 details of the included cases. Study subject IDs used are for the purpose of this study and are not

181 known to anyone outside the research group.

182

183 Next generation sequencing

184 Genomic DNA was extracted from peripheral blood samples of subjects and parents according to 185 standard procedures. Exome sequencing on DNA of subjects P2, P3, P12, P15, P18 was performed as

186 described elsewhere (7) in Macrogen, Korea. Briefly, target enrichment was performed with $2 \mu g$

187 genomic DNA using the SureSelectXT Human All Exon Kit version 6 (Agilent) to generate barcoded

188 whole-exome sequencing libraries. Libraries were sequenced on the HiSeqX platform (Illumina) with 189 50x coverage. Quality assessment of the sequence reads was performed by generating QC statistics

190 with FastQC. The bioinformatics filtering strategy included screening for only exonic and

191 donor/acceptor splicing variants. In accordance with the pedigree and phenotype, priority was given

192 to rare variants (<0.01% in public databases, including 1000 Genomes project, NHLBI Exome Variant

193 Server, Complete Genomics 69, and Exome Aggregation Consortium [ExAC v0.2]) that were fitting a

194 recessive (homozygous or compound heterozygous) or a de novo model and/or variants in genes

195 previously linked to neuropathy, developmental delay, and other neurological disorders. Next

196 generation sequencing for other samples was carried out using a number of methods with different

197 analysis platforms and pipelines used depending on the centre where sequencing was performed

(Supplementary Table 2). Recommendations of the Human Genome Variation Society were used to 198 199

describe the cDNA and protein sequence variants using NM 032900.6 and NP 116289.4 as the

200 reference. All the candidate variants were further verified, and family segregation was performed via 201 Sanger sequencing in-house or in the referring centres. Homozygosity mapping was performed on

- 202 Automap(8) and haplotype analysis was performed by plotting a colour banding of the variants
- 203 flanking the pathogenic ARHGAP19 variants for affected individuals and control samples. By
- 204 comparing the banding patterns of patients and controls, the status of being a founder/recurrent
- 205 variant was investigated. In the case of founder variants, we estimated the age of the most recent
- 206 common ancestor (MRCA) using the length of shared haplotypes between patients(9).
- 207

208 Multiple sequence alignment

- 209 To examine the conservation of substituted amino acid positions, we performed multiple sequence
- 210 alignments of ARHGAP19 across multiple different species. ARHGAP19 protein sequences for each
- 211 species were retrieved from UniProt using their respective accession codes (Supplementary Table 3).
- Alignments were performed using the MAFFT algorithm in Jalview (v2.11.2).
- 213

214 Protein structure modelling and in silico mutagenesis

- 215 The predicted wild-type ARHGAP19 protein structure was retrieved from the AlphaFold Protein
- 216 Structure Database (10) using its UniProt accession code (Q14CB8). Three-dimensional protein
- 217 structures were visualised using PyMol (v.2.5.2). To examine variant effects on three-dimensional
- 218 protein structure, in silico mutagenesis for identified missense substitutions was performed through
- the PyMol 'mutagenesis' function. For nonsense and frameshift variants, mutant protein structures
- were generated using the open-source AlphaFold v2.0 (AlphaFold2) pipeline (10) with the input
- being FASTA files of the mutant amino acid sequences. The resultant protein structures were then
- aligned to the wild-type ARHGAP19 protein structure within PyMol. AlphaMissense substitution
- scores for identified *ARHGAP19* missense variants were downloaded and extracted from resources
 generated by Cheng *et al* (11).

225 Calculation of free energy changes

- 226 To investigate the impact of *ARHGAP19* variants on protein stability, free energy changes between
- the wild-type and mutant proteins were calculated using FoldX v5.0.(12) Free energy change
- 228 predictions were only performed on missense substitutions within high confidence regions (pLDDT >
- 229 90) of the AlphaFold2-predicted protein structure.(13) The AlphaFold2 derived wild-type ARHGAP19
- 230 protein structure was energy minimised and prepared for mutagenesis with the 'RepairPDB' and
- 231 'BuildModel' commands in FoldX, respectively. Subsequent free energy calculations were performed
- with the 'Stability' command, and differences in free energy were determined by subtracting the
- free energy value of the wild-type protein monomer from that of the mutant protein ($\Delta G_{MUT} \Delta G_{WT}$).
- 234 Calculations were replicated 10 times with default parameters for each substitution. Substitutions
- 235 were classified as having a destabilising effect on protein folding if the free energy difference ($\Delta\Delta G$) 236 was >1.6 kcal/mol (12, 14, 15).
- 237

238 Cell culture of primary dermal fibroblasts

- 239 Primary dermal fibroblasts were obtained from skin biopsies of subjects in family 5 (P5 (F5-II:2)
- 240 (c.419G>A), family 6 (P6 (F6-II:7) (c.203T>C) and family 10 (P11 (F10-II:1) (c.85A>G) and age/ gender
- 241 matched control individuals. Fibroblasts were cultured in Dulbecco's modified Eagle medium
- 242 (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; GE Healthcare)
- and penicillin-streptomycin (100 U/mL and 100 mg/mL, respectively; Thermo Fisher Scientific). For
- all experiments, the same passage number of subject and control fibroblasts was used. Primary
- fibroblasts were regularly tested for mycoplasma contamination and confirmed to be mycoplasma
- 246 free. 247

248 Generation and culture of iPSCs

- 249 Healthy control iPSCs were obtained through the *StemBANCC Consortium*. Patients-derived
- 250 fibroblasts (P5 (F5-II:2) and P6 (F6-II:7)) were reprogrammed by non-integrating Sendai viral vectors
- 251 at Oxford StemTech (Oxford, United Kingdom). All iPSC lines were subject to quality control checks,

- 252 including flow cytometry for pluripotency markers, global screening array karyotyping, and
- 253 mycoplasma test. iPSCs were plated in Matrigel-coated 6-well plates and maintained in mTesR1 254 (StemCell Technologies).
- 255

256 Differentiation of iPSCs to spinal motor neurons

257 iPSCs were differentiated into MNs using a protocol previously published (16). Briefly, iPSCs were 258 dissociated with accutase and resuspended in a 10mm2 Petri dish to form embryoid bodies (EBs). 259 Differentiation medium consisted of (1:1 DMEM/F12-Neurobasal media, supplemented with N2, 260 B27, 2 mM L-glutamine, 1% Pen-Strep, 0.1 mM β-ME; all from ThermoFisher Scientific), with 10 μM 261 Y-27632 (Tocris), 0.1 µM LDN 193189, 20 µM SB431542, and 3 µM CHIR-99021 (Cambridge 262 Bioscience). Media was replaced every 2-3 days, with the addition of the following small molecules: 100 nM retinoic acid (RA, Sigma Aldrich) from day 2; 500 nM Smoothened Agonist (SAG, Sigma 263 264 Aldrich) from day 4; 10 µM DAPT (Cambridge Bioscience) from day 9. LDN 193189, SB431542 and 265 CHIR-99201 were discontinued on day 7. The neurotrophic factors BDNF, CNTF and GDNF 266 (Peprotech) were added to the differentiation medium from day 11, at a concentration of 10 ng/mL. 267 On day 14, EBs were dissociated, and post-mitotic neurons were seeded on poly-L-ornithine (Sigma 268 Aldrich) and laminin (Biotechne) coated plates. Eleven days after seeding cells were fixed for 269 immunocytochemistry and harvested for RNA and protein extraction. 270

271 **Migration assay**

272 Migration assays were performed and analysed as previously described(17). 100,000 cells were 273 resuspended in serum-free medium and plated on the top chamber (24-well transwell insert, Falcon: 274 353097). Cells were incubated at 37°C for 24h, which allowed migration towards the bottom 275 chamber containing complete medium with 10% FBS. Cells on the bottom surface of the insert 276 were fixed in 10% formalin (BioShop: FOR201) and stained with a crystal violet solution. Ten 277 images were taken for each transwell insert using a Nikon inverted microscope camera with a

- 278 10X objective lens (Nikon Eclipse TE300 Inverted microscope). Quantitative analysis was assessed 279 using Image J software. Data represent the fold change relative to wild type cells obtained from 280 at least three independent experiments.
- 281

282 Wound healing scratch assay

15,000 cells were seeded in 100 μ L of culture medium into sterile transparent 96-well plates and 283 284 incubated for 24h. A scratch wound was made in the confluent cell monolayer of each well using the 285 IncuCyte 96-well WoundMaker from Essen Bioscience as described in manufacturer's manual. After 286 carefully removing the cellular debris, 100 µL of culture medium was added to each well. Cell images 287 were captured every two hours using IncuCyte Live-Cell Imaging Systems (Essen BioScience, USA). 288 Images were analysed using the IncuCyte S3 software (2019A) to calculate cell confluency over time.

289

290 RNA isolation, cDNA synthesis, and quantitative real-time PCR (RT-gPCR)

Total RNA was extracted from cultured primary fibroblasts of subjects P5 (F5-II:2), P6 (F6-II:7), and 291

292 P11 (F10-II:1) and controls and from iPSC motor neuron of subjects P5 (F5-II:2) and P6 (F6-II:7) and

- 293 controls (using QIAGEN RNeasy extraction kit). gDNA purification was performed with DNA-free™ 294 DNase (Thermofisher). RNA concentration and purity of the samples were assessed using
- 295 NanoDrop equipment (NanoDrop Technologies Inc., Wilmington, DE). 0.5 µg total RNA was reverse
- 296 transcribed (Superscript III, Thermofisher). Technical triplicates of RT-qPCR samples were prepared
- 297 as a 10 µL approach with the Fast SYBR™ Green Master Mix (Thermofisher), 500 nM of each primer,
- 298 and 1 µl of the reverse transcription reaction. Primer sequences for RT-qPCR are described in
- 299 Supplementary Table 6. RT-qPCR was performed using the QuantStudio 3 Real-Time PCR System
- 300 (Thermo Fisher Scientific) equipped with QuantStudio Design&Analysis Software v1.4.3 (Thermo
- 301 Fisher Scientific). The PCR conditions included a pre-run at 95°C for 5 min, followed by 40 cycles of
- 302 30 s at 95°C, 30 s at 58°C and 45 s at 72°C. PCR amplification specificity was determined by melting

- 303 curve analysis with a range from 60°C to 95°C. The values of the cycle threshold (CT) of the target 304 mRNAs were normalized to the mRNA of *RPL18*. For relative gene expression, the comparative cycle 305 threshold ($\Delta\Delta$ CT) values were calculated with the QuantStudio Design&Analysis Software (Thermo
- 306 Fisher Scientific) with *RPL18* as housekeeping gene and expressed as x-fold change to controls.
- 307

308 RNA sequencing and analysis

- RNA sequencing was performed on RNA from subjects P5 (F5-II:2), P6 (F6-II:7) and P11 (F10-II:1) as 309 310 well as 3 controls using the Illumina TruSeg Stranded mRNA Library Prep kit. Pools were sequenced 311 using the Illumina NovaSeq 6000 Sequencing system to generate 100 bp paired-end reads with an 312 average read depth of ~100 million reads per sample. RNA sequencing raw data was mapped to 313 human reference genome assembly hg38 using STAR (18). Gene count tables were imported into R 314 environment to analyse differential gene expression patterns using DESeq2 package (19). For gene 315 enrichment analysis, pathfindR package was employed (20). Briefly, Biogrid database was used for 316 mapping the genes to protein-protein interaction network, with their associated p-values. The 317 resulting active subnetworks were filtered based on the significant genes they contain. The filtered
- 318 subnetworks were then enriched by the related cellular pathways. This was followed by hierarchical
- 319 clustering to group biologically relevant pathways. Major pathways with enrichment fold greater
- than 2 were selected for plotting per sample expression scores.

321 Western blotting

- Fibroblasts of subjects P5 (F5-II:2), P6 (F6-II:7) and P11 (F10-II:1) and controls and fibroblast-derived iPSc motor neurons of patients subjects P5 (F5-II:2) and P6 (F6-II:7) and controls were harvested in
- ice-cold RIPA buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% NP-40; 0.5% DOC [sodium
- deoxycholate]; 0.1% SDS [sodium dodecyl sulfate]) supplemented with Mini Protease Inhibitor
- 326 (Roche) and lysed for 60 min on ice. Cell debris was removed by centrifugation for 10 min. Protein
- 327 extracts were separated on 4-12 % SDS polyacrylamide gel under denaturing conditions and
- 328 transferred to polyvinylidene fluoride membranes. Membranes were blocked followed by incubation
- 329 with a ARHGAP19 primary antibody (Santa Cruz Biotechnology; 1:500) overnight at 4°C. After
- 330 washing, membranes were incubated HRP-linked anti-mouse secondary antibody (#G-21040
- 331 Invitrogen; 1:10,000) at room temperature for 1 h. After washing, immunoblots were digitally
- imaged using a Machine iBright 750 (invitrogen). Exposure time was optimized to avoid saturation.
- Bands were automatically defined, and intensities were determined using the build-in band
- detection tool of the Image Lab v6.0 software (Bio-Rad). GAPDH (ab9484, Abcam; 1:10000) was used
- as a loading control. Blots were repeated in duplicates and statistics were performed using Graph
- Pad Prism. The significance between the variables was shown based on the p value obtained (ns indicates p > 0.05, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).
- 338

339 Protein expression and purification

- Recombinant wild type and mutant GST-tagged ARHGAP19 GAP domain proteins were expressed in
 BL21 (DE3) bacteria and purified using glutathione-sepharose beads as previously described (21).
 PreScission protease (GenScript) was used for the cleavage of the GST tag and elution of the purified
 ARHGAP19 GAP proteins. Eluted proteins were concentrated using Amicon Ultra-4 centrifugal filters
 (MilliporeSigma), resolved by SDS-PAGE followed by Coomassie blue staining. Proteins were
- 345 quantified using bovine serum albumin (BSA) as standard.
- 346

347 In vitro GAP assay

- The GAP activity of ARHGAP19 wild type and protein mutants was assessed using the RhoGAP assay
- biochem kit (BK105, Cytoskeleton) according to manufacturer's instructions and recommendations.
- 350 Briefly, 1.5 μg of purified ARHGAP19 protein was mixed with His-RhoA protein and GTP for 20 min at
- 351 37 °C. CytoPhos reagent was added to the reaction mixture for 10 min at room temperature before
- 352 measuring the absorbance at 650nm with Infinite M200 Pro Microplate reader (TECAN).
- 353

354 Drosophila stocks and husbandry

Flies were raised on standard fly food at 25°C in 12 h light: 12 h dark cycles. All experiments and

- 356 crosses were conducted in these conditions unless otherwise specified. The following Drosophila
- 357 stocks were obtained from the Bloomington Drosophila stock center: *y*[1] *w*[*]; *P*{*Act5C-GAL4-*
- 358 w}E1/CyO (actin-Gal4; BDSC #25374), [1] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.HMS03522}attP40 (UAS 359 RhoGAP54D shRNA; BDSC #54051), y[1] w[*];
- 360 *TI{GFP[3xP3.cLa]=CRIMIC.TG4.1}RhoGAP54D[CR02433-TG4.1]/SM6a* (RhoGAP54D-Gal4; BDSC
- 361 #92267), y[1] w[*]; P{w[+mC]=tubP-GAL4}LL7/TM3, Sb[1] Ser[1] (tubulin-Gal4; BDSC #5138), and
- 362 w[*]; P{w[+mC]=UAS-NsImb-vhhGFP4}3 (BDSC #38421). The RhoGAP54D::GFP fusion allele (w[*];
- 363 *RhoGAP54d:GFP:2Ma*; MKRS/TM6B) was generated via CRISPR-Cas9 gene editing, as described
- 364 previously (22) . The w[*]; P{Act5C-GAL4-w}E1/CyO insertion was outcrossed into an isogenized
- background (iso31) for five generations, with the X-linked y[1] marker removed in the process
 (Supplementary Table 7).
- 367

368 Generation of a Drosophila RhoGAP54D null allele

- 369 The *RhoGAP54D*^{KO} loss of function allele was generated using CRISPR/Cas9 mediated homologous
- 370 recombination. We generated homologous recombination donor and guide plasmids to replace the
- 371 RhoGAP54D reading frame from amino-acids (AA) T4 to L1004 (numbered according to the isoform
- RA, 1004 AA in length) by a *mw* gene flanked by two attP Phi31 recombination sites using the
- pcrispr-del (23) and the pcFD5 (24) plasmids. pcFD5 was a gift from Simon Bullock (Addgene
- plasmid # 73914 ; http://n2t.net/addgene:73914 ; RRID:Addgene_73914). To generate the pCRISPR-
- del- RhoGAP54D targeting the *RhoGAP54D* locus, the genomic 5' HR1 (~1kb) and 3' HR2 (~1kb)
- 376 regions were PCR amplified using the following primers: HR1 5'-
- 377 CCGGGCTAATTATGGGGTGTCGCCCTTCGCGGATCTCCGTAGACGCCGTTC and 5'-
- 378 <u>ACTCAAAGGTTACCCCAGTTGGGGCACTAC</u>TGCTTCCATGCAATCTGTGTGGTTTATCC, HR2 5'-
- 379 ACTCAAAGGTTACCCCAGTTGGGGCACTACGACACGTTTAGCTTGGCCGCG and 5'-
- 380 <u>GCCCTTGAACTCGATTGACGCTCTTCTGTA</u>CAAGCCACCCCACACACTGAG to clone them in pCRISPR-del
- 381 (underlined nucleotides matching the plasmid sequence used for cloning). We used 4 distinct gRNA,
- two in Nter and two in Cter to the *RhoGAP54D* locus, cloned in tandem in gRNA pCFD5 (Addgene
- 383 #73914) plasmid to generate 2 pCFD5-RhoGAP54D guide plasmids using the following primer: 5-
- 384 <u>GCGGCCCGGGTTCGATTCCCGGCCGATGCA</u>AGATTGCATGGAAGCAACGA<u>GTTTTAGAGCTAGAAATAGCAA</u>
 385 G and 5'-
- 386 <u>ATTTTAACTTGCTATTTCTAGCTCTAAAAC</u>TTTCGCCCGGATACTTCTCGTGC<u>ACCAGCCGGGAATCGAAC</u> as 387 well as 5'-
- 388 <u>GCGGCCCGGGTTCGATTCCCGGCCGATGCA</u>AGATTGCATGGAAGCAACGA<u>GTTTTAGAGCTAGAAATAGCAA</u>
 389 <u>G</u> and <u>5'</u>-
- 390 <u>ATTTTAACTTGCTATTTCTAGCTCTAAAAC</u>TATCCATCGTTGCTTCCATG<u>TGCACCAGCCGGGAATCGAAC-</u>.
- 391 Cloning was performed by primer annealing and ligation, or by SLIC. All regions amplified by PCR as
- 392 well as junctions between tag and genomic sequences were checked by sequencing. *RhoGAP54D*^{KO}
- allele was then generated by co-injection of the pCRISPR-del- RhoGAP54D (300ng/ml) and each of
- the guide plasmid (25ng/ml) in embryos of the PBac{y+-attP-9A}VK00027 (BDSC #51324) line.
- 395 Embryos injection was performed by BestGene transgenesis services. The RhoGAP54D^{KO} genomic
- deletion and locus organization were confirmed by PCR and sequencing.

397 Drosophila activity assays

- 398 To quantify locomotion in adult male flies, the Drosophila Activity Monitor (DAM; Trikinetics inc.,
- 399 MA, USA) was used as described previously(25). Individual flies were housed in glass tubes
- 400 containing 4% sucrose and 2% agar, bisected by an infrared beam, allowing activity to be quantified
- 401 as the number of beam breaks made by each fly over time. Fly movement was measured at 25°C
- 402 across 24 h comprised of 12 h light and 12 h dark period, from which total activity and activity during
- 403 ZT (zeitgeber time) 12-13 were quantified. Experiments were performed on 3-7 day old male flies. All
- 404 flies were acclimatised to the DAM conditions for 48 h prior to the experimental period.

405

406 Drosophila immuno-histochemistry

407 Adult brains were dissected and immuno-stained as described previously(26). Briefly, brains were

- fixed for 20 min at room temperature via incubation in 4% paraformaldehyde (MP Biomedicals), and
- 409 blocked for 1 h in 5% normal goat serum in Phosphate Buffered Saline containing 0.3% Triton-X
- 410 (Sigma-Aldrich) (0.3% PBT). Primary antibodies were as follows: mouse anti-Bruchpilot (BRP) (nc82,
- 411 Developmental Studies Hybridoma Bank), 1:50; rabbit anti-dsRed (Clontech, Cat. no. #632496),
- 412 1:1000. Secondary antibodies were: goat anti-rabbit AlexaFluor-555 (ThermoFisher, Cat. no.
- 413 #A32732), 1:1000; and goat anti-mouse AlexaFluor-647 (ThermoFisher Cat. no. #A21236), 1:500.
- Brains were incubated in primary and secondary antibodies overnight at 4°C. Brains were washed
- then mounted and imaged in SlowFade Gold anti-fade mounting solution (ThermoFisher Scientific).
 Images were taken using a Zeiss LSM 710 confocal microscope with an EC 'Plan-Neoflar' 20x air
- 417 objective. Images were analysed using ImageJ.
- 418

419 Quantitative PCR

420 Total RNA was extracted from dissected brain tissue of actin > UAS-RhoGAP54D shRNA and actin >

- 421 UAS-mCherry shRNA (control) adult male flies using standard phenol chloroform extraction. RNA
- 422 concentration and purity were assessed using NanoDrop equipment (NanoDrop Technologies Inc.,
- 423 Wilmington, DE). 0.5 μg of total RNA was reverse transcribed to generate cDNA (Superscript III,
- 424 Thermofisher). Technical duplicates of the qPCR samples were prepared as a 10 µL approach with
- 425 the Fast SYBR[™] Green Master Mix (Thermofisher), using 500 nM of each primer (forward:
- 426 ATGGAAGCAACGATGGATACG; reverse: CTCGTGACAGGGGAGATCGAA), and 1 μ l of the reverse
- 427 transcription reaction. qPCR was performed using the QuantStudio 3 Real-Time PCR System (Thermo
- Fisher Scientific) equipped with QuantStudio Design&Analysis Software v1.4.3 (Thermo Fisher
 Scientific). The PCR conditions included a pre-run at 95°C for 5 min, followed by 40 cycles of 30 s at
- 429 Scientific). The PCR conditions included a pre-full at 95 C for 5 min, followed by 40 cycles of 50 s at 430 95°C, 30 s at 58°C and 45 s at 72°C. PCR amplification specificity was determined by melting curve
- 431 analysis with a range from 60°C to 95°C. The values of the cycle threshold (CT) of the target mRNAs
- 432 were normalized to the mRNA of RpL4 (forward primer: TCCACCTTGAAGAAGGGCTA; reverse primer:
- 433 TTGCGGATCTCCTCAGACTT). For relative gene expression, the comparative cycle threshold (ΔCT)
- 434 values were calculated with the QuantStudio Design&Analysis Software (Thermo Fisher Scientific)
- 435 with RpL4 used as a control gene. *RhoGAP54D* expression was normalised to *RpL4* and expressed as
- 436 a fold change relative to *actin* > UAS-*mCherry* shRNA controls.
- 437

438 Danio rerio functional analyses

- 439 Wild-type zebrafish, Danio rerio, were housed and bred within UCL Fish Facility at 28.5°C on a 14h 440 day/10h dark cycle. All experiments were conducted under licences awarded by the UK Animal 441 (Scientific Procedures) Act 1986 implemented by the Home Office in England. For whole-mount in 442 situ hybridization, zebrafish embryos were first fixed in 4% paraformaldehyde (PFA/PBS) overnight at 443 4°C, dechorionated, and dehydrated in methanol at -20°C. A T7 bacteriophage promoter containing 444 ampliconof arhgap19 was synthesised from cDNA libraries at three different developmental stages: 445 24 hours post-fertilization (hpf), 48 hpf, and 5 days post-fertilization (dpf). A primer set was designed 446 with the T7 bacteriophage promoter sequence incorporated at the 5' end of the reverse primer for 447 antisense probe production (Forward primer: 5'-GGCCGAATTCTCACAGCTAC-3'; Revers primer: 5'-448 TAATACGACTCACTATAGG TCTTACACGCGCTGATGAAC-3'). A Digoxigenin-labeled antisense probe 449 was synthesized using a DIG-RNA Labeling Kit (T7 polymerases, Roche). Whole-mount in situ 450 hybridization (WISH) was carried out as previously described (27) on 48 hpf, 72 hpf, and 5 dpf larvae. 451 For the color reaction, NBT/BCIP Stock Solution (Roche) was used in the staining buffer. The stain was fixed in methanol and embryos mounted in 3% methylcellulose for imaging. 452
- 453
- The zebrafish arhgap19 gene (ZDB-GENE-100922-157) is an ortholog of *Homo sapiens* ARHGAP19; there is 59.95 % nucleotides similarity and 55 % amino acid similarity between the zebrafish and

456 human loci. No zebrafish paralogs corresponding to ARHGAP19 exist. CRISPR/Cas9-mediated F0

457 biallelic knockout was performed as described previously (28). Six crRNAs were designed according
458 to their on-target and off-target scores. The six sgRNAs sequences were: 1) 5'-

459 <u>ACGCTCCTCAAGAGTTTCTT</u>-3', 2) 5'-<u>CAAGATGTCTGCTCACAACC</u>-3', 3) 5'- <u>CAAGAGTTTCTTGGGAGAAT</u> 460 3', 4) 5'-<u>GAACCCAAGACTCCCAACGC</u>-3', 5) 5'-<u>TGACTTTCATCCCAATGACG</u>-3', 6) 5'-

461 <u>AGGCAACAAGACGAGTTTTC</u>-3'. Each cRNA was annealed to tracrRNA and complexed to Alt-R S.p.
 462 HiFi Cas9 nuclease to form a ribonucleoprotein (RNP). A pool of three RNPs were co-injected into

463 one to two-cell stage zebrafish embryos. For each RNP pool, 0.5nL and 1nL volumes were injected

464 into the yolk of batches of embryos. At 5 dpf, three zebrafish larvae were randomly selected for

- 465 genomic DNA extraction to determine the targeting efficiency by Illumina Miseq (Eurofins). PCR
- amplification targeting RNP cut sites were performed for each crRNA and products purified, pooled
- and sent for next generation sequencing. Primers included universal adaptors for MiSeq
- 468 (Supplementary Table 5). Cut efficiency was calculated for each RNP using CRISPResso2 (29).

An antisense translational blocking Morpholino (MO, GeneTools.LLC) against the AUG-containing
 mRNA sequence (5'-GGCCATCTTTCATCTTCCGTTTGAA-3') and a splice MO targeting the Exon1-

- 471 Intron1 (E1I1) boundary (5'-ATAAATCTTCGTTACCTTCTGTCTC-3') was designed to knockdown
- 472 arhgap19 function. MOs were diluted to the desired working concentrations (3 ng, 4 ng, 6 ng, and
- 473 8ng per embryo) before use. Microinjection was performed by injecting 0.5-1nL morpholino solution
- into one to two-cell stage embryos in the yolk. Dose dependent phenotyping was used to identify an
 appropriate concentration that balanced survival with specific phenotypic changes.
- 476

477 Danio rerio behavioural assays

Zebrafish larvae at 5 dpf were transferred into individual wells of a square flat-bottomed96-well
plate. Baseline locomotor activity was recorded for a duration of 30 minutes and analysed using the
DanioVision (Noldus, Netherlands) monitoring chamber, which was integrated with the EthoVision
XT 14 video tracking software (Noldus, Netherlands). Plots were analysed for distance travelled (in
millimeters), total time spent and velocity. For assessment of muscle integrity, zebrafish larvae at 5
dpf were fixed and their skeletal muscle was analysed for total birefringence using polarized light
microscopy on a Nikon SMZ1000 stereo microscope.

485

486 Danio rerio Immuno-histochemistry

Zebrafish larvae at 5 dpf were permeabilized with 10ug/ml Proteinase in PBS Tween (0.2%, PBT)K, 487 488 followed by 20 mins fixation in 4% PFA. Larvae were then blocked with goat serum (5% in PBT), and 489 incubated with anti-tubulin mouse monoclonal antibody (1:500 dilution; T6793-2ML, Sigma) 490 overnight at 4°C. After four washing steps (PBT), larvae were incubated with Alexa Fluor™ anti-491 mouse 568 secondary antibody (1:1000 dilution; A-11004, ThermoFisher) in the dark at 4°C. For 492 nucleus detection, larvae were incubated with DAPI (1:1000 dilution; D1306, ThermoFisher) under 493 dark conditions at 4°C. Embryos were washed again in PBT (four times) and imaged using a Nikon 494 A1R confocal microscope to assess motor neuron morphology. Confocal fluorescent images were 495 processed and code depth adjusted with FIJI/ImageJ while motor neuron quantification was 496 conducted using the SNT plugin.

497

498 Statistical Analysis

Statistical evaluations were carried out using IBM SPSS Statistics. One-way ANOVA and Welch's t-test
 were used for statistical comparisons between groups with calculated standard deviations/errors of
 the mean. For *Drosophila* work, we run non-parametric tests for normal distribution using Shapiro Wilk test for normality. Normally distributed datasets were subject to tests as stated. Non-normal

- 503 were subject to Mann-Whitney U-test or Kruskal-Wallis test with Dunn's post-hoc test (single or
- 504 multiple comparisons respectively). Significant differences were determined at a threshold of p <
- 505 0.05. The corresponding p-values are provided in the figure legends.
- 506

507 Data availability

508 The data that supports the findings of this study are available within the paper and in the

509 supplementary material. Whole-exome sequencing data are not publicly available due to privacy or

510 ethical restrictions. The identified variants reported in this manuscript were submitted to the LOVD

511 database (https://databases.lovd.nl/shared/genes/ARHGAP19), with the LOVD variant IDs:

512#0000971425, #0000971426, #0000971427, #0000971440, #0000971442, #0000971444,

513 #0000971446, #0000971450, #0000971466, #0000971468, #0000971470, #0000971471,

514 #0000971473, #0000971474, #0000971475, #0000971478, #0000971479 and #0000971480.

515 Results

516 Genetic Findings

517 We identified 20 unrelated families with 25 affected individuals harbouring biallelic variants in

518 ARHGAP19 (Figure 1B for variant schematic within the protein and Figure 2A for pedigrees). All

variant alleles identified in the families were either absent or observed only as heterozygous at

520 extremely low frequencies in over 1.5 million alleles across multiple publicly available and private

521 genetic variant databases (range 0–0.003). Four variants (4/16, 25%) were observed in more than 522 one family. Notably, p.His196Gln*fs**9, p.Leu68Pro, p.Gln151Lys and p.Leu228His variants were found

523 in 2 independent Arab, 4 independent Turkish, and 2 independent Bangladeshi/Afghani families,

- 524 respectively.
- 525

526 Haplotype plots of homozygous regions encompassing *ARHGAP19* variants were compared to assess

527 if the same causative variants are inherited from a common ancestor (Supplementary Figure 1). The

528 chr10-97259559-A-T (p.Leu228His) and chr10:97263447-G-GT (p.His196Gln*fs**9) variants are

529 recurrent since patients harbouring the shared variants have different haplotypes. Patients F14-II:2

and F7-II:1 harbour the chr10-97263582-G-T variant (p.Gln151Lys) and share a large 3.4 MB long

haplotype. MRCA analysis shows that this founder variant has emerged about 26 generations ago

532 (equivalent to 520 years). Variant chr10-97265979-A-G (p.Leu68Pro) is the other founder variant

that we detected in patients F15-II:3 and F6-II:7 who harbour the same haplotype. The shared

homozygous region is 3.0 MB in length, and they have inherited the variant from a common

ancestor back to about 29 generations ago (equivalent to 580 years).

536 Clinical Delineation

537 Table 1 summarises the core clinical features of affected probands with ARHGAP19 defects (see

538 Supplementary Table 1 for Neurophysiology and for detailed clinical vignettes please contact the

539 corresponding author to request access to these materials). A total of 25 individuals were identified

from 20 families and 9 (36%) were male. They were from a wide range of ancestral backgrounds

- including Pakistan, Turkey, Egypt, Syria, Bangladesh, Spain, Australia, Brazil, Iran, Dubai and
- 542 Afghanistan. 72% (18/25) were born from consanguineous parents. The mean (median) age at
- 543 symptom onset (AAO) was 9.9 (10.0) years, and at assessment was 22.8 (16.0) years. The presenting 544 symptom was a motor deficit of the lower limbs in 91% (21/23), and 64% (14/22) had some form of
- 544 symptom was a motor deficit of the lower limbs in 91% (21/23), and 64% (14/22) had some form of 545 clinical sensory involvement (symptoms or signs), but as the disease progressed it typically remained

either exclusively motor or motor predominant. Patients typically had a length-dependent pattern

547 (17/23, 74%, which includes those with only distal lower limb involvement) of lower motor neuron

548 signs of areflexia and muscle atrophy, with foot drop. Lower limb-predominant disease was seen

(distal > proximal weakness, with normal upper limbs) in 17% (4/23) and upper limb predominant

550 disease seen in 9% (2/23). Foot deformity was present in 80% (16/20), with a recurrent, but not

551 ubiquitous finding of increased sandal gap (access to photos of deformities mentioned can be

accessed by contacting the corresponding author). However, the presence brisk knee jerks, and
 preserved lower limb reflexes each in 9% (3/23) respectively suggests some mild UMN involvement

- in these individuals. There were no consistent features outside of the peripheral nervous system.
- 555

556 A prominent feature of the phenotype is its significant asymmetry in terms of limb involvement,

557 seen at onset or at assessment in 61% (14/23). Two cases presented acutely with upper limb

weakness on a background of mild or subclinical widespread neuropathy. Neurophysiology 558 559 (Supplementary Table 1) was performed in 20 individuals. Detailed numerical study data was 560 available in 15/20; five cases had a report only. All had a motor neuropathy, with variable sensory 561 involvement. Evidence of motor conduction slowing was seen or described in 50% (10/20) and 562 conduction block in 20% of the studies with numerical data (3/15). Combining clinical and 563 neurophysiological data the following phenotypes were seen: CMT-intermediate (CMTi) (2/25), 564 CMT2 (6/25), hereditary motor neuropathy (HMN, 7/25) and CMT (indeterminate from 565 neurophysiology, or no neurophysiology available, 10/25). Within the cases of CMT2/HMN, 38% 566 (5/13) demonstrate conduction slowing that does not meet criteria for CMTi or CMT1 (upper limb 567 motor conduction velocities 25-45 m/s) either because the slowing was patchy or subtle, or the 568 phenotype was HMN. The mean (median) ulnar motor velocity was 42.6 (45) m/s (range 25-58 m/s, n = 11).

569 570

571 It is difficult to comment on disease progression with only a single assessment in many cases, but in 572 some individuals, from the history there is a more rapid progression than is typical for CMT, with 573 mean (median) duration between AAO and assessment of 13.0 (5) years; the mean difference is 574 skewed by some outlying cases of mildly affected relatives. Two cases presented with acute upper

- 575 limb weakness. The first (P13 (F12-II:1)), a male infant carrying the recurrent variant p.Leu228His
- 576 presented with bilateral upper limb weakness over fifteen days. Spinal imaging was normal, but
- 577 neurophysiology was never performed. Upper limb function improved over time, but the patient
- 578 sadly died before 5 years of age. The second (P17 (F15-II:2)), a teenage female carrying the recurrent
- p.Leu68Pro, presented with acute left-hand weakness, on a background of more widespread
- 580 conduction slowing neuropathy. She was treated with intravenous immunoglobulin (Ig) for
- presumed chronic inflammatory demyelinating polyneuropathy (CIDP), with no clear response.
 Interestingly, P6 (F6-II:7), a female who carries the same homozygous variant, had walking difficulty
- from infancy but presented in her teenage years with a four-month deterioration in left lower limb
- weakness. She had a conduction slowing neuropathy in the lower limbs. She is currently beingtreated with subcutaneous Ig for presumed CIDP.

587 In silico modelling

588 Multiple sequence alignments performed for ARHGAP19 orthologs across 11 animal species (Figure 589 2A), anchored to the human ARHGAP19 protein sequence, showed that most variants affect highly 590 conserved amino acid residues. Of note, the variants affecting moderately conserved residues 591 (Asn160, Arg407 and GIn415) are frameshift or nonsense. All variants segregated with disease within 592 the families (Figure 2A). Computational variant prediction tools such as MutationTaster, SIFT and 593 PolyPhen predict the functional impact of all but two variants as mainly damaging and deleterious. 594 According to the American College of Medical Genetics and Genomics and the Association for 595 Molecular Pathology (ACMG-AMP) system for variant classification, all the variants are classified as 596 either likely pathogenic or pathogenic. The characteristics of all reported variants are summarized in 597 Supplementary Table 2.

598

586

599 Three-dimensional visualisation of ARHGAP19 wild-type and mutant variants as predicted by 600 AlphaFold2 (Figure 3B) depicts that mutant protein structures for frameshift variants show 601 substantial deviation from the wild-type protein (Figure 3C), likely disrupting the RhoGAP domain 602 structure. Nonsense substitutions modelled using AlphaFold2 (Figure 3D) display a similar structure 603 to the WT protein, with greater variation only occurring in the final alpha-helix and the subsequent 604 C-terminal end of the protein. Missense substitutions showed little or no change when modelled with the AlphaFold2 pipeline. As such, the 'mutagenesis' function on PyMol was used to predict 605 606 changes in protein structure and/or folding upon substituted amino acid residue incorporation into 607 the sequence (Figure 3E). All substitutions showed changes in steric hindrance with nearby amino 608 acid residues. The calculated free energy changes for p.(Gly140Asp), p.(Leu141Trp), p.(Gln151Lys),

- 609 p.(Leu228His), and p.(Pro311Arg) substitutions show a decrease in free energy >1.6 kcal/mol,
- 610 indicating a protein destabilising effect (Figure 3F). Notably, three substitutions are predicted to
- 611 result in protein instability with high confidence (p.(Gly140Asp), p.(Leu141Trp), and p.(Pro311Arg)).
- 612 In addition, the p.(Gln151Lys) variant shows an increase in free energy and thus an increase in
- 613 protein stability. Using further analysis with AlphaMissense, of the nine missense variants identified,
- seven (77.78%) are predicted to be likely pathogenic (Supplementary Table 4).
- 615
- 616 Functional Characterisation

617 Western Blotting and qPCR

618 Given the potential loss of function in homozygous ARHGAP19 individuals, we investigated gene 619 expression levels through the use of qPCR and protein levels through Western blotting of ARHGAP19 620 in fibroblasts from families harbouring the c.85A>G (p.Asn29Asp), c.419G>A (p.Gly140Asp), c.203T>C 621 (p.Leu68Pro) variants and in fibroblast-derived iPSc of P5 (F5-II:2) and P6 (F6-II:7). Whist gene 622 expression remained unchanged in both fibroblasts and motor neurones, western blotting 623 assessment of ARHGAP19 protein levels revealed significant reduction of ARHGAP19 in iPSC motor 624 neurons of patients as opposed to controls (Figure 4).

625

626 RNA Sequencing

- 627 Differential expression analysis showed that there is no difference in ARHGAP19 RNA levels between
- 628 the ARHGAP19 deficient patient fibroblasts and healthy controls (log2 fold change = -0.29 and p-
- 629 value = 0.43). Thus, we hypothesised that despite having the same expression level, mutant
- ARHGAP19 may affect downstream genes in its signalling pathway, causing the disease phenotype.
- 631 Principle component analysis (PCA) showed a distinctive RNA expression pattern between the
- 632 patients and controls (Supplementary Figure 2). Pathway enrichment analysis showed that the
- expression patterns are significantly different in 3 pathways: cell cycle, motor proteins, and muscle
- 634 cells' cytoskeleton (Figure 4D). Cellular pathways were further analysed to infer their expression
- 635 levels in patients compared to controls, which showed that the 3 mentioned pathways are
- 636 downregulated in ARHGAP19 patients (Figure 4E).

637 In vitro GAP assay shows loss of GAP activity in ARHGAP19 variants in the GAP domain

638 ARHGAP19 has been previously reported for its RhoGAP activity. Interestingly, several mutations in 639 ARHGAP19 are clustering around the region encoding the GAP domain (Figure 1C). To investigate the

- ARHGAP19 are clustering around the region encoding the GAP domain (Figure 1C). To investigate the
 GAP activity of these ARHGAP19 variants, the GAP domain of ARHGAP19 or the mutated GAP
- 641 proteins were expressed as GST fusion proteins in *E. coli* for *in vitro* GAP assays. Specific GAP activity
- toward RhoA was measured as the rate of inorganic phosphate released by GTPase-mediated GTP
- 643 hydrolysis. RhoA alone showed little intrinsic GTPase activity, while the addition of wild type
- 644 ARHGAP19 significantly accelerated the rate of RhoA-mediated GTP hydrolysis (Figure 5). Two
- 645 ARHGAP19 missense mutations, p.Gly140Asp, and p.Gln151Lys, abrogated the GAP activity of
- 646 ARHGAP19, decreasing the GTPase hydrolysis rate to the basal level. Another ARHGAP19 mutation,
- p.His196Gln*fs**9, which led to a truncated GAP domain of ARHGAP19, completely abolished the GAP
- activity as evidenced by severely impaired phosphate release (Figure 5A). Altogether, these results
- demonstrate that these mutations in the GAP domain of ARHGAP19 are dominant loss-of-functionalleles, abolishing its GAP activity.
- 651

652 Patient-derived fibroblast cells demonstrate impaired cell migration

653 To further analyse the consequences of the *ARHGAP19* variants on cellular morphology, we derived

- 654 fibroblasts from the patients of family 5 (c.419G>A), family 6 (c.203T>C) and family 10 (c.85A>G),
- paired with age/ gender matched health control (wild type). Since the *in vitro* GAP assay indicated
- 656 that ARHGAP19 c.419G>A (p.Gly140Asp) show defective GAP activity towards RhoA (Figure 5A), we
- 657 hypothesized that variants in *ARHGAP19* may affect cell proliferation and migration. *ARHGAP19*
- variants and wild type fibroblasts showed no significant differences in cell proliferation (Figure 5B).
- 659 However, patient-derived fibroblasts carrying the Gly140Asp and Asn29Asp mutations had a

- significant reduction in cell migration compared to control cells using both a Boyden chamber
- 661 migration and wound healing assays (Figures 5C and D). In contrast, patient-derived fibroblasts
- harbouring the Leu68Pro showed no significant differences with control cells (Figures 5C and D).
- 663 These results confirm the GAP defective function of the *ARHGAP19-* Gly140Asp mutant and suggest
- that the GAP activity of the *ARHGAP19*-Asn29Asp mutant may also be altered.

665 The ARHGAP19 ortholog RhoGAP54D promotes movement in Drosophila

666 To explore the consequences of ARHGAP19 loss of function *in vivo*, we first utilised the fruit fly, 667 Drosophila melanogaster. The Drosophila genome contains a single ARHGAP19 ortholog termed 668 RhoGAP54D, which exhibits 51% amino-acid similarity and 31% identity to the human ARHGAP19 669 protein (Supplementary Figure 3). To examine the expression of RhoGAP54D in the Drosophila nervous system, we utilised a CRIMIC T2A-GAL4 enhancer trap in intron 3 of the RhoGAP54D locus 670 (30), which we term *RhoGAP54D*^{CRIMIC-Gal4} and which results in expression of Gal4 in the pattern of 671 the endogenous gene (Figure 6A). Driving expression of a UAS-CD4::TdTomato reporter via 672 *RhoGAP54D*^{CRIMIC-Gal4} allowed us to label *RhoGAP54D*-positive cells in the adult fly brain and thoracic 673 674 ganglion (Figure 6B). In agreement with previously published single-cell RNAseq data (31, 32) 675 (Supplementary Figure 4A), this approach revealed sparse expression of *RhoGAP54D*, including 676 projections to the antennal mechanosensory motor centre (AMMC) and isolated cell bodies within 677 the brain and thoracic ganglion (Figure 6B). In addition, we noted RhoGAP54D-driven TdTomato 678 signal surrounding the central and thoracic synaptic regions, suggesting that *RhoGAP54D* may be 679 expressed in the perineural and/or subperineural glia (SPG) that form the blood-brain barrier

- 680 covering the central and thoracic neuropil domains (Figure 6B) (33).
- 681

682 Given that ARHGAP19 variants perturb movement in humans, we tested whether reducing

- 683 RhoGAP54D expression similarly disrupted movement in *Drosophila*. Since RhoGAP54D is likely
- expressed in a variety of distinct cell-types, we used a global driver (*actin*-Gal4) in concert with an
- shRNA predicted to cleave *RhoGAP54D* mRNA in exon 3 of the primary transcript to induce
- ubiquitous RhoGAP54D knockdown (Figure 6A). Using quantitative PCR, we confirmed that
- 687 expression of this shRNA caused an ~ 50% reduction in *RhoGAP54D* mRNA expression
- 688 (Supplementary Figure 4B). We then used the *Drosophila* Activity Monitor (DAM) system (25) to test 689 how reducing RhoGAP54D expression affected locomotor activity in adult flies (Supplementary

690 Figure 4C). In 12 h light: 12 h dark conditions, wild-type *Drosophila* exhibit crepuscular peaks of

- activity centred around lights-on and lights-off, interspersed by periods of low activity (Figure 6C).
 Global RhoGAP54D knockdown reduced both total activity occurring over 24 h and activity occurring
- 692 Global MildCAP S4D MillCAP S4D MildCAP S4D MildCAP S4D MildCAP S4D MildCA
- 695

696 To complement the above data we utilised degradFP, a genetic system that promotes degradation of 697 GFP-tagged fusion proteins via the ubiquitin pathway (34). Ubiquitous expression of degradGFP 698 components in a background homozygote for a *RhoGAP54D::GFP* knock-in allele (22) similarly 699 reduced overall and peak movement relative to RhoGAP54D::GFP homozygote controls (Figure 6F-700 H). As a final confirmation of the above results, we generated a RhoGAP54D null allele 701 (RhoGAP54D^{KO}) through CRISPR-Cas9 gene editing (Figure 6D). Comparison of RhoGAP54D^{KO} heterozygote and homozygote flies again revealed reduced overall and peak movement in 702 *RhoGAP54D*^{KO} homozygotes relative to heterozygote controls (Figure 6I-K). Collectively, these data 703 demonstrate that RhoGAP54D promotes robust locomotor activity in Drosophila, supporting the 704

- 705 genetic link between variants in the human ortholog ARHGAP19 and disrupted movement.
- 706

707 Danio rerio arhgap19 is important for motor neuron function

708 We next utilised zebrafish (*Danio rerio*) to examine the molecular, cellular, and developmental

- impact of ARHGAP19 loss of function in a vertebrate system. To analyse the endogenous expression
- 710 pattern and subcellular localization of zebrafish *arhgap19* during development, we conducted

711 whole-mount in situ hybridization (WISH) assays at three different embryonic stages, utilizing

- digoxigenin-labelled antisense RNA probes specific for *arhgap19*. ISH analyses revealed a ubiquitous
- expression pattern of arhgap19 across multiple brain regions, notably in the forebrain and hindbrain
- compartments. This expression was predominantly enriched within neural tissues at the 48 hpf.
- 515 Specifically, heightened arhgap19 expression was observed in anatomically defined regions such as
- the cerebrum, thalamus, tuberculum, and tegmentum (Figure 7B). Intriguingly, a temporal
 downregulation of arhgap19 expression was evident as development progressed; by 5 dpf, th
- downregulation of arhgap19 expression was evident as development progressed; by 5 dpf, the
 expression levels had substantially diminished (Figure 7B).
- 719

To investigate the functional role of Arhgap19 in neuronal and motor development, we generated an

- 721 F0 biallelic knockout mutant model utilizing CRISPR/Cas9 system. Genomic deletions were
- introduced at three selected loci within the zebrafish arhgap19 gene—exons 2, 4, and 5—informed
- by considerations of targeting efficiency and potential off-target effects (Figure 7A). Of the initial
- batch of 62 eggs, 32 (51.6%) were successfully fertilized. Embryos were monitored on a daily basis,
- with dead ones discarded. Those that survived were sacrificed at 5 dpf for genotyping and
 subsequent analysis. NGS sequencing showed that sgRNAs 2, 4, and 5 manifested high gene-editin
- subsequent analysis. NGS sequencing showed that sgRNAs 2, 4, and 5 manifested high gene-editing
 efficiency, with respective average modification rates of 96.1%, 99.7% and 94.6%. Conversely, sgRNA
- 3 exhibited suboptimal performance, achieving a comparatively low modification rate of merely
- 729 11%.
- 730

To evaluate the changes in behaviour in the arhgap19 mutant model, we collected 24 zebrafish

- 732 larvae at the 5 dpf and analysed their motor activity. Metrics such as the total duration of
- 733 movement, aggregate distance traversed, and mean velocity were measured. Behavioural assays
- demonstrated that *arhgap19* knockout induced conspicuous motor deficits. Larvae in both mutant
 (CRISPants) groups exhibited decreased motor activity, alongside idiosyncratic and involuntary
- movements. In contrast, larvae from the Uninjected Control (UIC) group exhibited normal locomotor
- 737 behaviour, exploring the well's periphery (Figure 7C).
- 738

739 Statistical analysis revealed significant discrepancy in motor parameters among the groups.

740 Specifically, larvae from both CRISPants groups were significantly different in the total travel

distance (Figure 7D; one-way ANOVA, F(2, 69) = 13.954, and p < 0.0001, followed by Welch T test.

742 CRISPant 0.5nL, t(45.82) = -2.376 and p = .022; CRISPant 1nL, t(41.939) = -5.418 and p < 0.0001).

- Likewise, the mean velocity also showed significant differences between mutant and control groups (Figure 5E; one-way ANOVA, F(2, 69) = 13.954, and p < 0.0001, followed by Welch T test. CRISPant
- 0.5nL, t(45.82) = -2.376 and p = .022; CRISPant 1nL, t(41.939) = -5.418 and p < 0.0001). Larvae from
 the CRISPants 1nL group swam approximately twice as slow compared to those from the UIC group.
- 747

To investigate the impact of arhgap19 knockout on muscular architecture, we quantitatively
assessed the birefringence intensity of zebrafish skeletal muscle at the 5-dpf, employing a polarizing
light stereomicroscope for imaging. Statistical analysis of the birefringence levels revealed no
significant difference between the control group and the three knockout groups (Figure 7G; one-way
ANOVA, F(2, 8) = 2.904, p=0.131). These findings strongly suggest that the skeletal muscle integrity
remains largely intact in the absence of arhgap19. Consequently, the motor deficits observed in the

- behavioural analyses are more likely attributed to impairments in motor neuron function rather than
- 755 muscular deficiencies.
- 756

757 To investigate the effects of *arhgap19* knockout on primary motor neurons, we employed

758 immunostaining techniques complemented by confocal microscopy for visualization. Notably, a

- more robust axonal bundle was observed in both CRISPant groups (Figure 7H). Quantitative
- assessments were carried out to analyze both axonal length and branching complexity. In *arhgap19*
- 761 CRISPant larvae, the branching density of the Caudal Primary (CaP) Motorneurons was higher than

762 that of the control group (Figure 5I; one-way ANOVA, F(2, 43) = 21.341 and p < 0.0001, followed by 763 Welch T test with Bonferroni's adjustment. CRISPant 1nL, t(22.271) = 6.33 and ***p < 0.0001). 764 Moreover, axonal length was markedly affected in *arhgap19* CRISPants. Statistical analysis revealed 765 a notable reduction in the average length of CaP and Middle Primary (MiP) motorneurons in 1nL 766 injected CRISPants , measuring 577.2 μ m and 391.2 μ m, respectively, in contrast to the control

767 values of 1012.5 μm and 639.8 μm. (Figure 7J; one-way ANOVA, F(2, 43) = 41.936 and p < 0.0001, 768

- followed by Welch T test with Bonferroni's adjustment. CRISPant 0.5nL, t(26.647) = -4.943 and ***p 769 < 0.0001; CRISPant 1nL, t(24.101) = -10.092 and ***p < 0.0001) Particularly, the axons of CaPs in
- arhqap19 CRISPants exhibited diminished length which failed to reach the ventral musculatures. 770
- 771 Furthermore, embryos injected with arhgap19 splice site and translation blocking morpholinos also
- 772 exhibited branching abnormalities similar to those observed in CRISPants mutants (Supplementary
- 773 Figure 5). Taken together, these results indicated that impaired motor neuron developmental were
- 774 attributable to the loss of arhgap19.
- 775

776 Discussion

777 We show that biallelic ARHGAP19 variants are a novel cause of inherited early-onset neuropathy. 778 We identified 25 individuals harbouring missense and nonsense variants both within the functional 779 GAP domain as well as outside this structural domain of ARHGAP19. The patients had a motor-780 predominant neuropathy with AAO almost exclusively in the first two decades of life. The clinical 781 phenotype was generally length-dependent, but there are some unusual features including 782 frequency conduction slowing +/- conduction block, prominent asymmetry, in some individuals 783 relatively rapid progression and upper limb onset. There was no observable genotype-phenotype 784 correlation at the first examination; mean AAO of variants in GAP versus non-GAP domain 9.0 vs 785 11.6 years (p = 0.32, n = 15 and 8 respectively) and mean ulnar motor conduction velocity 41.0 vs 786 44.8 m/s (p = 0.62 n = 5 and 5). However, longitudinal studies would help better delineate the 787 disease progression and any genotype-phenotype correlation.

788

789 Haplotype analysis using genetic data from our cohort as well as from control databases suggested 790 that p.His196GInfs*9 is unlikely to be from a recent common ancestor and possibly suggests that 791 two independent ARHGAP19 mutational events within Arabian Middle Eastern populations. 792 Moreover, p.Gln151Lys and p.Leu68Pro variants are founder effect variants, probably originating in 793 Turkey given the ethnicity of patients. Variant p.Gln151Lys which affects a highly conserved residue 794 within the GAP domain, could have a significant structural or functional role. Additionally, this 795 variant affects the same N-terminal catalytic stretch where the arginine motif at codon 143 is found, 796 and therefore might have a comparable mechanistic effect as do other AHRGAP19 variants identified 797 nearby, i.e. p.Gly140Asp, p.Leu141Trp. Together with p.Leu228His and p.Asn239Lys, they are 798 predicted to disrupt the domain's structure and subsequently its function as a GTPase-activating 799 protein in a variety of cellular processes (3, 35). Similarly, previously reported variants in the Rho-800 GAP domain of Myo9b, abrogate GAP activity (36). Interestingly, the corresponding MYO9B gene has 801 recently been associated with a subtype of CMT2 and isolated optic atrophy (37). Other variants which increase free energy, such as p.Gln151Lys, may cause a deleterious effect to protein folding or 802 803 stability through other mechanism. We note that free energy changes were calculated using the 804 AlphaFold2-derived ARHGAP19 protein. A recent study concluded that AlphaFold is not immediately 805 applicable when calculating free energy changes for predicted protein structures (38). However, 806 results were based on the first iteration of AlphaFold. Conversely, another study showed that free 807 energy changes using AlphaFold2-predicted protein models consistently matched those of 808 experimentally determined structures, particularly in high confidence regions (pLDDT > 90) (13). 809 Thus, until an experimental ARHGAP19 protein structure is generated, it is important that in silico 810 investigations of variant impact are complemented by corresponding functional studies. 811

The phenotype of conduction slowing in a motor(-predominant) neuropathy is unusual in CMT, limited to very few genes. Notably, recessive variants in the GEF gene *PLEKHG5* cause this phenotype and have been showed to cause both loss of large, myelinated fibres and thin myelination seen on nerve biopsy, and motor axonal degeneration in a knockout mouse model (39, 40). Combined with the conduction slowing seen with biallelic variants in *ARHGEF10*, mechanistically this would suggest that Rho GTPase activity, mediated by these GEF and GAP proteins, is implicated in a process that

- 818 may involve both myelin and axonal pathologies.
- 819

820 Data derived from three global in vivo loss-of-function Drosophila models and three CRISPR-Cas9 821 mediated knockout zebrafish models demonstrate a conserved role for ARGHAP19 orthologs in 822 promoting locomotor activity across metazoan species, supporting the above genotype-phenotype 823 correlations in human patients harbouring ARGHAP19 mutations. We observed more pronounced 824 axonal bundles and a significantly increased number of axonal branches in all experimental mutant 825 zebrafish groups, suggesting that ARGHAP19 LOF may cause CMT in part by perturbing the 826 cytoskeleton of motoneurons. This hypothesis is consistent with previous reports of RhoA playing a 827 critical role in modulating cytoskeletal dynamics, including the mediation of stress fibre formation 828 and focal adhesions(41), and facilitating axonal outgrowth and branching (42). Further 829 transcriptomics analysis provided evidence that pathways associated with motor proteins, cell cycle 830 and muscular cytoskeleton are downregulated, further explaining that clinical features observed in 831 our patients might be due to alteration in these physiological pathways. Of note, there are some 832 upregulated cellular functions in the patients, including the ferroptosis and cytokine-cytokine

- 833 receptor interactions.
- 834

835 How might ARHGAP19 mutations perturb the cytoskeletal network in motor neurons? In this work, 836 the pathogenicity of ARHGAP19 variants p.Gly140Asp, p.Gln151Lys and p.His196Glnfs*9 are 837 supported by in vitro GAP activity assays which show that variants within GAP domain cause 838 complete loss of GAP activity. ARHGAP19 stimulates the intrinsic low GTPase activity of RhoA 839 thereby negatively regulating the RhoA/ROCK pathway. Variants causing loss of GAP activity of 840 ARHGAP19 may therefore cause overactivity of RhoA with further consequences in downstream 841 effectors such as ROCK activation which has important functions in actin organisation, cell migration, 842 and axon outgrowth and guidance. Importantly, this is in line with in vitro data from patient-derived 843 fibroblasts harbouring p.Asn29Asp and p. Gly140Asp variants, that show significant decrease in cell 844 migration using cell migration assays. Together, these results reveal that GAP defective ARHGAP19 845 variants lead to altered RhoA activity thereby altering cell migration and cytoskeletal dynamics. 846 Interestingly, protein expression analysis by Western blot revealed significant reduction in 847 ARHGAP19 in iPSC motor neurons of patients compared to controls. Taken together, our findings are 848 consistent with the patients' phenotype and functional assays, explaining that the muscular and 849 motor defects observed in patients as well as animal models could be due to the dysregulation of 850 the ARHGAP19 related signalling cascade. We provide evidence for loss-of-function of ARHGAP19 as 851 the pathomechanism of the disease and suggest that the loss of function might be more robust in 852 motor neurons.

853

Of note, variant p.Leu68Pro showed no change in the migration and wound healing assays as opposed to WT controls. Interestingly, the two patients with this variant in our cohort were first suspected to have an autoimmune cause of neuropathy and were put on intravenous lg for treatment of presumed CIDP with no improvement. These patients also have an upper limb involvement, and it is noteworthy that even if the variant lies outside the GAP domain, it is predicted pathogenic using various *in silico* methods.

- 861 Our findings do not fully elucidate the mechanism of axonal damage caused by ARHGAP19
- 862 deficiency. Regarding the animal models created in this study, we were not able to investigate the

expression of RhoGAP54d in the fly peripheral nervous system and the zebrafish model showed no
expression of the protein ortholog in its periphery. On the basis of frequent conduction slowing and
the early-onset phenotype observed, it will therefore be important to examine peripheral
myelination in the human subjects, as well as use better techniques for spatial localization and
quantitative expression in models of ARHGAP19 deficiency.

867 868

869 Despite the theoretically simple on/off switch model of Rho, the Rho GTPase signalling pathway has 870 a more sophisticated picture. The high number of GAP and GEF proteins – 66 and 80 respectively, 871 which outnumber Rho proteins, coupled with unclear specificity of the proteins, means that 872 understating their signalling activities as well as role in disease, remain challenging. Nevertheless, 873 overactive RhoA signalling in neurons, be it due to genetic variations or imbalance between 874 signalling molecules, has been reported in Charcot-Marie-Tooth disease. It is increasingly emerging 875 that this is an important pathway not only in neuronal health but also in disease. Hence, modulation 876 of this pathway may represent a potential strategy for future therapeutic treatments.

877

878 Acknowledgments

879 We thank the patient and relatives for consent to be part of the study as well as the clinicians for 880 helping with patient phenotyping. The families were collected as part of the SYNaPS Study Group 881 collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding 882 (WT093205 MA and WT104033AIA) and research was conducted as part of the Queen Square 883 Genomics group at University College London, supported by the National Institute for Health 884 Research University College London Hospitals Biomedical Research Centre. This work was partly 885 supported by an MRC strategic award to establish an International Centre for Genomic Medicine in 886 Neuromuscular Diseases (ICGNMD) MR/S005021/1 and ND, SE, CR, PT, MGH, MMR and HH received 887 direct support from this award. JP is supported by Medical Research Future Fund (MRFF) Genomics 888 Health Futures Mission (APP2007681) and by the Australian Government Research Training 889 Program. LVdV is supported by a predoctoral fellowship of the Research Fund - Flanders (FWO) 890 under grant agreement N°11F0921N. TS is member of the European Reference Network for Rare 891 Neuromuscular Diseases (ERN EURO-NMD). JB is supported by a Senior Clinical Researcher mandate 892 of the Research Fund - Flanders (FWO) under grant agreement N°1805021N. ANB gratefully 893 acknowledges the support of SVIKV and the use of the services and facilities of the Koc University 894 Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Head of 895 Strategy and Budget. We thank collaborator Simon Bullock (University of Cambridge) for plasmids, 896 and Florencia di Pietro for characterization of the RhoGAP54D loss of function allele. JECJ was 897 funded by an MRC Senior Non-Clinical Fellowship (MR/V03118X/1). Work in the Bellaïche group is 898 funded by the CNRS, the INSERM and the Institut Curie as well as by the ANR (TiMecaDiv 899 20CE13000801) grant. TBH was supported by the Deutsche Forschungsgemeinschaft (DFG, German 900 Research Foundation – 418081722, 433158657), and the European Commission (Recon4IMD - GAP-901 101080997). This work was supported in part by the Fund for Scientific Research (FWO-Flanders) 902 (research grants G048220N and G0A2122N to A.J.), the Research Fund of the University of Antwerp 903 (doctoral grant to C.A.), the Association Belge contre les Maladies Neuromusculaires' (ABMM-904 Telethon) (research grantsto A.J.), the French Muscular Dystrophy Association (AFM-Telethon, 905 research grant 23708 to A.J.). JPark was supported by the Clinician Scientist program "PRECISE.net" 906 funded by the Else Kröner-Fresenius-Stiftung. Work in the Lamarche-Vane group funded by Natural 907 Sciences and Engineering Research Council of Canada grant RGPIN/04809-2017 and CIHR project 908 grant PJT-180367. Leif Leclaire holds a CIHR master studentship. RH is supported by the Wellcome 909 Discovery Award (226653/Z/22/Z), the Medical Research Council (UK) (MR/V009346/1), the 910 Addenbrookes Charitable Trust (G100142), the Evelyn Trust, the Stoneygate Trust, the Lily 911 Foundation, Ataxia UK, Action for AT, the Muscular Dystrophy UK. This research was supported by 912 the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those 913 of the authors and not necessarily those of the NIHR or the Department of Health and Social

- 914 Care.We are also grateful to Queen Square Genomics at the Institute of Neurology University College
- 915 London, supported by the National Institute for Health Research University College London Hospitals
- 916 Biomedical Research Centre, for the bioinformatics support.
- 917

918 Online resources

- 919 CPDB web tool, <u>http://cpdb.molgen.mpg.de/</u>
- 920 Ensembl, <u>http://www.ensembl.org/i</u>
- 921 FastQC, <u>http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</u>
- 922 GATK documentation, <u>https://software.broadinstitute.org/gatk/</u>
- 923 Human Genome Variation Society, <u>http://www.hgvs.org</u>
- 924 Mutation Taster version 2, <u>http://www.mutationtaster.org/</u>
- 925 PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/
- 926 SIFT, <u>http://sift.jcvi.org/</u>
- 927 University of California—San Francisco (UCSC) Genome Browser, <u>https://genome.ucsc.edu/</u>
- 928 Jalview, <u>https://www.jalview.org/</u>
- 929 UniProt, <u>https://www.uniprot.org/</u>
- 930 PyMol, https://pymol.org/2/
- 931 AlphaFold Protein Structure Database, <u>https://alphafold.ebi.ac.uk/</u>
- 932 FoldX, <u>https://foldxsuite.crg.eu/</u>
- 933 DIOPT http://flybase.org/reports/FBgn0034249.html
- 934







Figure 1. A. Pathway showing GTPase-activating proteins (GAPs) such as ARHGAP19 responsible for
 promoting cycling of Rho GTPases between the active GTP-bound and the inactive GDP-bound

939 conformations. GEF: Guanine nucleotide Exchange Factor, GDP: Guanine nucleotide diphosphate,

940 GDI: Guanine Nucleotide Dissociation Inhibitor, Pi: dihydrogen phosphate. B-C. Schematic diagrams

of ARHGAP19 gene (B) and protein (C). Introns are not to scale. Exon numbers are according to the
 canonical transcript (NM_032900.6). Amino acid changes are according to the reference sequence
 NP_116289.4.



944

Figure 2. Genetic presentation of individuals harbouring *ARHGAP19* variants. Pedigrees of affected
 families showing segregation of the biallelic *ARHGAP19* variants identified.

947

948



950 Figure 3. Investigating the effect of ARHGAP19 variants in silico. A. Multiple sequence alignment of ARHGAP19 orthologs shows conservation of identified variants in different species. B. Predicted 951 952 wild-type ARHGAP19 protein structure (UniProt: Q14CB8) using AlphaFold2, coloured with the per-953 residue confidence score (pLDDT). Dark blue, very high confidence (pLDDT > 90); light blue, 954 confident (90 > pLDDT > 70); yellow, low confidence (70 > pLDDT > 50); orange, very low confidence 955 (pLDDT < 50). AlphaFold-generated mutant protein structures (red) derived from the identified frameshift C. and nonsense D. variants and aligned to the wild-type ARHGAP19 protein (green). E. 956 957 The effect of identified missense variants on three-dimensional ARHGAP19 structure. Wild-type 958 residues are coloured green and mutant residues are coloured red. F. Predicted free energy changes $(\Delta GMUT - \Delta GWT)$ for missense variants on protein stability. Calculations were performed on 959 960 variants within the very high confidence regions (pLDDT >90) of the AlphaFold-generated ARHGAP19 961 protein. Data are given as mean ± s.d.





963

Figure 4. Western blot and RNA-Seq analyses confirm downregulation of ARHGAP19 as well as cell 964 cycle, motor and muscular cytoskeleton pathways. A-B. Protein expression levels of ARHGAP19 in 965 966 iPSc-derived motor neuronal lines (A) and patient-derived fibroblasts (B). Fibroblasts from P5 (F5-967 II:2), P6 (F6-II:7) and P11 (F10-II:1) harbouring the c.419G>A (p.Gly140Asp), c.203T>C (p.Leu68Pro) 968 and c.85A>G (p.Asn29Asp) variants respectively were analysed by Western blot, as well as fibroblast-969 derived iPSc neurons from P5 (F5-II:2) and P6 (F6-II:7) patients. C. Volcano plot showing log2 of fold 970 change in ARHGAP19 mutants compared to controls and -log10 (adjusted p value). D. Pathway 971 enrichment: differentially expressed genes with p-value < 0.005 were selected for performing 972 pathways enrichment analysis. Top 10 pathways with the highest enrichment scores were plotted, 973 showing 3 cellular pathways highly enriched with dozens of affected genes and a very low p-value: 974 cell cycle, motor proteins, and cytoskeleton in muscle cells. E. Pathway scores per sample: enriched

- 975 pathways were analysed to compare their expression levels in patients and controls. Some pathways
- are overexpressed in patients while most of them are downregulated.



978 979 Figure 5. ARHGAP19 variants have defective GAP-activity and cell migration. A. In vitro GAP activity assay measuring the GTPase rate of RhoA in the absence (intrinsic) or the presence of GAP domain 980 from ARHGAP19 wild type (WT) or mutants. Data are presented as means ± SEM from three 981 independent experiments (n=3; ****, p<0.0001; one-way ANOVA) B. MTT assays in fibroblasts from 982 healthy controls (wt#223 and wt#1419) and ARHGAP19 mutants (n=3). C and D. Fibroblasts cells 983 984 were subjected to the Boyden chamber migration assay (C) or wound healing scratch assay (D) as 985 described in Materials and methods (n=4). Data are presented as means ± SEM (*p<0.05, **p<0.01, 986 ns, not significant, one-way ANOVA) 987

977





990

Figure 6. *ARHGAP19* ortholog *RhoGAP54D* promotes movement in *Drosophila melanogaster*. A. Schematic of the *RhoGAP54D* locus. Exons – white blocks; untranslated regions (UTRs) – grey blocks;

introns – line. Insertion site of the *RhoGAP54D*^{CRIMIC-Gal4} element and exonic region targeted by
 RhoGAP54D shRNA are shown (red arrows). **B.** Confocal images illustrating *RhoGAP54D*-driven
 membrane-tagged CD4::TdTomato expression in the adult male *Drosophila* brain and thoracic
 ganglion. Brain: yellow arrow points to projections close to the antennal mechanosensory motor
 contor. Thoracia ganglion: red arrows point to isolated call bedies. Note the CDAvEdTervete sized

995 center. Thoracic ganglion: red arrows point to isolated cell bodies. Note the CD4::TdTomato signal

996 surrounding Bruchpilot (BRP)-labelled neuropil domains. C. Patterns of locomotor activity in flies 997 globally expressing RhoGAP54D shRNA (actin > RhoGAP54D shRNA) and driver/shRNA alone 998 controls. White bar: lights on; black bar: lights off. D-E. Number of beam breaks across 24 h (D) or 999 during ZT12-13 (E), a period of peak activity. n = 15-16. F-H. Patterns of locomotor activity (F), total 1000 (G) and peak (ZT12-13; H) beam breaks in adult flies harbouring a RhoGAP54D GFP fusion allele and 1001 expressing deGradFP components, enabling degradation of the RhoGAP54D::GFP fusion protein, and a RhoGAP54D::GFP homozygote control. N = 18 and 24 respectively. I-K. Patterns of locomotor 1002 1003 activity (I), total (J) and peak (ZT12-13; K) beam breaks in adult flies heterozygous or homozygous for 1004 the *RhoGAP54D*^{KO} null allele. N = 16 and 20 respectively. Central line in dot plots: mean. Error bars: standard error of the mean (SEM). * P < 0.05, **P < 0.005, ***P < 0.0005, one-way ANOVA with 1005 1006 Dunnett's post-hoc test (D), Kruskal-Wallis test with Dunn's post-hoc test (E), Mann-Whitney U-test 1007 (G, K), or t-test with Welch's correction (H, J) 1008





1010 Figure 7. Danio rerio arhgap19 is important for motor neuron function. A. Schematic

- 1011 representation of ten exons to cover the complete coding region. The position of the sgRNA targets 1012 are indicated (green illustrate the highest level of knockdown efficiency). **B.** *arhgap19* expression at 1013 three different embryonic stages in zebrafish. At 48 hpf, WISH signal of *arhag19* is localized in the 1014 forebrain and hindbrain regions; scale bar = 1000 μ m. Rho: Rhombencephalon (hindbrain); Tel: 1015 Telencephalon; Th: Thalamus; Tu: Tuberculum; Tgm: Tegmentum. **C-E.** Behavior analysis of UIC and 1016 *arhgap19* mutant zebrafish larvae at 5-dpf. (C) reveals the swimming trajectories of each larva.
- 1017 Quantification of total travel distance (D) and travel velocity (E) of UIC and *arhgap19* mutant
- 1018 zebrafish larvae for 30 mins (UIC, CRISPant 0.5nL, CRISPant 1nL: n = 24). Each bar represents mean (±
- 1019 SEM). Asterisks above the bars indicate significant difference (*P \leq 0.05, **P \leq 0.01, ***P \leq 0.001). **F**-
- G. UIC and *arhgap19* mutant zebrafish larvae at 5-dpf were evaluated for muscle integrity using
 birefringence. (F) A representative image of one larva from each treatment group; scale bar = 1000

1022 μm. Each bar in plot (G) represents average birefringence (± SEM) for all zebrafish larvae (UIC,

1023 CRISPant 0.5nL, CRISPant 1nL : n = 3). **H-J.** Spinal motor neurons morphogenesis defects in *arhgap19*

1024 mutant zebrafish larvae. (H) Confocal imaging analysis and three-dimensional reconstruction of

spinal motor neurons in UIC and *arhgap19* mutant groups at 5-dpf; scale bar = $100 \mu m$. (I) Axonal

branching number of Cap axons in UIC and *arhgap19* mutant zebrafish larvae. (J) Average axonal
 length of Cap (yellow) and Mip (blue) axons in UIC and *arhgap19* mutant zebrafish larvae. Each b

length of Cap (yellow) and Mip (blue) axons in UIC and *arhgap19* mutant zebrafish larvae. Each bar
 represents mean (± SEM). Asterisks above the bars indicate significant difference (*P ≤ 0.05, **P ≤

- 1029 0.01, ***P ≤ 0.001 , ****P ≤ 0.0001).
- 1030

1031 References

1032 1. Pisciotta C, Shy ME. Neuropathy. Handb Clin Neurol. 2018;148:653-65.

10332.Klein CJ. Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies. Continuum1034(Minneap Minn). 2020;26(5):1224-56.

10353.David MD, Petit D, Bertoglio J. The RhoGAP ARHGAP19 controls cytokinesis and1036chromosome segregation in T lymphocytes. J Cell Sci. 2014;127(Pt 2):400-10.

Niftullayev S, Lamarche-Vane N. Regulators of Rho GTPases in the Nervous System:
 Molecular Implication in Axon Guidance and Neurological Disorders. International journal of
 molecular sciences. 2019;20(6).

1040 5. Chen Z, Maroofian R, Basak AN, Shingavi L, Karakaya M, Efthymiou S, et al. Novel variants
1041 broaden the phenotypic spectrum of PLEKHG5-associated neuropathies. European journal of
1042 neurology. 2021;28(4):1344-55.

Marceaux C, Petit D, Bertoglio J, David MD. Phosphorylation of ARHGAP19 by CDK1 and
 ROCK regulates its subcellular localization and function during mitosis. J Cell Sci. 2018;131(5).
 Efthymiou S, Salpietro V, Malintan N, Poncelet M, Kriouile Y, Fortuna S, et al. Biallelic

mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination.
Brain : a journal of neurology. 2019;142(10):2948-64.

Quinodoz M, Peter VG, Bedoni N, Royer Bertrand B, Cisarova K, Salmaninejad A, et al.
 AutoMap is a high performance homozygosity mapping tool using next-generation sequencing data.
 Nature communications. 2021;12(1):518.

10519.Gandolfo LC, Bahlo M, Speed TP. Dating rare mutations from small samples with dense1052marker data. Genetics. 2014;197(4):1315-27.

105310.Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate1054protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.

1055 11. Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, et al. Accurate proteome1056 wide missense variant effect prediction with AlphaMissense. Science (New York, NY).
1057 2023;381(6664):eadg7492.

1058 12. Delgado J, Radusky LG, Cianferoni D, Serrano L. FoldX 5.0: working with RNA, small 1059 molecules and a new graphical interface. Bioinformatics (Oxford, England). 2019;35(20):4168-9.

Akdel M, Pires DEV, Pardo EP, Janes J, Zalevsky AO, Meszaros B, et al. A structural biology
 community assessment of AlphaFold2 applications. Nat Struct Mol Biol. 2022;29(11):1056-67.
 Ravenscroft G, Miyatake S, Lehtokari VL, Todd EJ, Vornanen P, Yau KS, et al. Mutations in
 KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy. Am J Hum Genet.

1064 2013;93(1):6-18.

1065 15. Mao K, Borel C, Ansar M, Jolly A, Makrythanasis P, Froehlich C, et al. FOXI3 pathogenic 1066 variants cause one form of craniofacial microsomia. Nature communications. 2023;14(1):2026.

1067 16. Rizzo F, Bono S, Ruepp MD, Salani S, Ottoboni L, Abati E, et al. Combined RNA interference 1068 and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-1069 Marie-Tooth type 2A. Cell Mol Life Sci. 2023;80(12):373.

1070 17. He Y, Goyette MA, Chapelle J, Boufaied N, Al Rahbani J, Schonewolff M, et al. CdGAP is a
1071 talin-binding protein and a target of TGF-β signaling that promotes HER2-positive breast cancer
1072 growth and metastasis. Cell Rep. 2023;42(8):112936.

1073 18. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal 1074 RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. 1075 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-19. 1076 seq data with DESeq2. Genome Biol. 2014;15(12):550. 1077 Ulgen E, Ozisik O, Sezerman OU. pathfindR: An R Package for Comprehensive Identification 20. 1078 of Enriched Pathways in Omics Data Through Active Subnetworks. Front Genet. 2019;10:858. 1079 21. Stewart K, Gaitan Y, Shafer ME, Aoudjit L, Hu D, Sharma R, et al. A Point Mutation in p190A 1080 RhoGAP Affects Ciliogenesis and Leads to Glomerulocystic Kidney Defects. PLoS genetics. 1081 2016;12(2):e1005785. 1082 22. di Pietro F, Osswald M, De Las Heras JM, Cristo I, Lopez-Gay J, Wang Z, et al. Systematic 1083 analysis of RhoGEF/GAP localizations uncovers regulators of mechanosensing and junction formation 1084 during epithelial cell division. Current biology : CB. 2023;33(5):858-74 e7. 1085 Pinheiro D, Hannezo E, Herszterg S, Bosveld F, Gaugue I, Balakireva M, et al. Transmission of 23. 1086 cytokinesis forces via E-cadherin dilution and actomyosin flows. Nature. 2017;545(7652):103-7. 1087 24. Port F, Bullock SL. Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs. 1088 Nature methods. 2016;13(10):852-4. 1089 Pfeiffenberger C, Lear BC, Keegan KP, Allada R. Locomotor activity level monitoring using the 25. 1090 Drosophila Activity Monitoring (DAM) System. Cold Spring Harb Protoc. 2010;2010(11):pdb 1091 prot5518. 1092 Wu JS, Luo L. A protocol for dissecting Drosophila melanogaster brains for live imaging or 26. 1093 immunostaining. Nat Protoc. 2006;1(4):2110-5. 1094 Coutelle O, Blagden CS, Hampson R, Halai C, Rigby PW, Hughes SM. Hedgehog signalling is 27. 1095 required for maintenance of myf5 and myoD expression and timely terminal differentiation in 1096 zebrafish adaxial myogenesis. Dev Biol. 2001;236(1):136-50. 1097 Kroll F, Powell GT, Ghosh M, Gestri G, Antinucci P, Hearn TJ, et al. A simple and effective F0 28. 1098 knockout method for rapid screening of behaviour and other complex phenotypes. Elife. 2021;10. 1099 Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, et al. CRISPResso2 provides 29. 1100 accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019;37(3):224-6. 1101 30. Lee PT, Zirin J, Kanca O, Lin WW, Schulze KL, Li-Kroeger D, et al. A gene-specific T2A-GAL4 1102 library for Drosophila. Elife. 2018;7. 1103 Davie K, Janssens J, Koldere D, De Waegeneer M, Pech U, Kreft L, et al. A Single-Cell 31. 1104 Transcriptome Atlas of the Aging Drosophila Brain. Cell. 2018;174(4):982-98 e20. 1105 32. Allen AM, Neville MC, Birtles S, Croset V, Treiber CD, Waddell S, et al. A single-cell 1106 transcriptomic atlas of the adult Drosophila ventral nerve cord. Elife. 2020;9. 1107 33. Freeman MR. Drosophila Central Nervous System Glia. Cold Spring Harb Perspect Biol. 1108 2015;7(11). 1109 34. Caussinus E, Kanca O, Affolter M. Fluorescent fusion protein knockout mediated by anti-GFP 1110 nanobody. Nat Struct Mol Biol. 2011;19(1):117-21. 1111 35. Amin E, Jaiswal M, Derewenda U, Reis K, Nouri K, Koessmeier KT, et al. Deciphering the 1112 Molecular and Functional Basis of RHOGAP Family Proteins: A SYSTEMATIC APPROACH TOWARD 1113 SELECTIVE INACTIVATION OF RHO FAMILY PROTEINS. The Journal of biological chemistry. 1114 2016;291(39):20353-71. 1115 Hemkemeyer SA, Vollmer V, Schwarz V, Lohmann B, Honnert U, Taha M, et al. Local Myo9b 36. 1116 RhoGAP activity regulates cell motility. The Journal of biological chemistry. 2021;296:100136. 1117 37. Cipriani S, Guerrero-Valero M, Tozza S, Zhao E, Vollmer V, Beijer D, et al. Mutations in 1118 MYO9B are associated with Charcot-Marie-Tooth disease type 2 neuropathies and isolated optic 1119 atrophy. European journal of neurology. 2023;30(2):511-26. 1120 Pak MA, Markhieva KA, Novikova MS, Petrov DS, Vorobyev IS, Maksimova ES, et al. Using 38. 1121 AlphaFold to predict the impact of single mutations on protein stability and function. PLoS One. 1122 2023;18(3):e0282689.

- 1123 39. Azzedine H, Zavadakova P, Plante-Bordeneuve V, Vaz Pato M, Pinto N, Bartesaghi L, et al.
- PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth
 disease. Hum Mol Genet. 2013;22(20):4224-32.
- 1126 40. Luningschror P, Binotti B, Dombert B, Heimann P, Perez-Lara A, Slotta C, et al. Plekhg5-
- regulated autophagy of synaptic vesicles reveals a pathogenic mechanism in motoneuron disease.Nat Commun. 2017;8(1):678.
- 1129 41. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of
- 1130 stress fibers and focal adhesions. J Cell Biol. 1996;133(6):1403-15.
- 1131 42. Chen H, Firestein BL. RhoA regulates dendrite branching in hippocampal neurons by
- decreasing cypin protein levels. J Neurosci. 2007;27(31):8378-86.

1133

Family	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Case	PT1 (F1- II:1)	PT2 (F2- II:5)	PT3 (F3- II:1)	PT4 (F4- II:1)	PT5 (F5- II:2)	PT6 (F6- II:7)	PT7 (F7- II:1)	PT8 (F8- II:2)	PT9 (F9- II:3)	PT11 (F10- II:1)	PT12 (F11- II:2)	PT13 (F12- II:1)	PT14 (F13- II:3)	PT15 (F14- II:2)	PT17 (F15- II:2)	PT18 (F16- II:1)	PT19 (F17- II:1)	PT20 (F18- II:1)	PT21 (F19- II:1)	PT25 (F21-IV:I)
Nucleotide change	c.261d up	c.585d upA	c.1243 C>T	c.1219 C>T	c.419G >A	c.203T >C	c.451C >A	c.1A>G	c.452d el	c.85A> G	c.932C >G	c.683T >A	c.585d upA	c.451C >A	c.203T >C	c.422T >G	c.717T >A	c.563d el	c.683T >A	c.818C>T
Amino acid change	p.Pro8 8Alafs* 43	p.His19 6Gln <i>fs</i> * 9	p.Gln4 15*	p.Arg4 07*	p.Gly14 0Asp	p.Leu6 8Pro	p.Gln1 51Lys	p.Met1 ?	p.Asn1 60Met <i>f</i> <i>s</i> *21	p.Asn2 9Asp	p.Pro3 11Arg	p.Leu2 28His	p.His19 6Gln <i>fs</i> * 9	p.Gln1 51Lys	p.Leu6 8Pro	p.Leu1 41Trp	p.Asn2 39Lys	p.Pro1 88Argfs *5	p.Leu2 28His	p.Pro273 Leu
Sex	м	м	F	F	м	F	F	F	м	м	м	м	F	м	F	F	F	F	м	F
Phenotype	CMT- MP**	CMT with CS*	dHMN with CS	CMT2- MP	dHMN	dHMN with CS	CMT with CS*	CMT2- MP	CMT2w ith CS**	CMT2- MP	CMT2- MP with CS	Unk*	CMT**	dHMN *	CMTi- MP	dHMN **	CMT with CS*	HMN with CS**	CMT2- MP	dHMN*
Consangui nity	Yes	No	Yes	No	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes
Age of onset (years)	6-10	11-15	6-10	6-10	10-20	infancy	11-15	11-15	11-15	26-30	11-15	0-5	n/a	11-15	11-15 [∆]	11-15	6-10	6-10	11-15	0-5
Symptom at onset	Falls	Walkin g difficult y	Falls	Dist LL weakn ess	Dist LL weakn ess	Walkin g difficult y	Dist LL weakn ess	Walkin g difficult y	Dist right LL weakn ess	Leg cramps	Dist LL weakn ess	Acute UL weakn ess	Unk	Falls	Acute left hand weakn ess	Dist LL weakn ess	Right leg weakn ess	Dist right LL weakn ess	Dist left LL weakn ess	Dist LL weaknes s
Asymmetr y	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	No	No	No	Unk	No	Yes	Yes	Yes	Yes	Yes	Yes
Clinical sensory involveme nt	No	Yes	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Unk	No	Yes	Yes	Unk	No	No	Yes
LL Areflexia	No	Brisk KJ, AJ	Yes	Yes	Yes	KJ present	Yes	KJ present	Yes	KJ brisk, AJ present , L Babins ki	KJ present	Unk	Unk	Yes	Brisk KJ, AJ present	Yes	Left AJ present	Yes	No	KJ present

Pattern of muscle weakness(MRC grade ADF/APF)	Dist LL L>R (4,3/4, 4)	Distal LL L>R (1,2)	LD (~3,0/4)	LD ('sever e')	LL predo minant dist > prox (0/0)	LD (~2,3/4)	LD (4/4)	LD (0/4)	LD (~1,3/5)	LL predo minant dist > prox (4/5)	LD (0/3)	UL > LL (Unk)	Unk	?LD (Unk)	Dist UL> LL (5/5)	LD (0,1/1)	Right dist LL only (Unk)	LL predo minant dist > prox (~1/?)	Dist LL L>R, (4,0/5)	LD (2/4)
Foot deformity	Pes cavus	Pes planus, hamme r toe	Pes cavus	Pes cavus	Nil	Pes cavus, SG	Pes cavus	Pes planus	Pes planus	Nil	Pes cavus	Nil	Unk	Pes cavus	Hamm er toe, SG	Pes cavus	Unk	Unk	No	Yes
Gait	Left foot drop	Unk	Steppa ge	Unk	Steppa ge	Steppa ge	Steppa ge	Steppa ge	Steppa ge	Steppa ge and waddle	Steppa ge	Unclea r	Unk	Steppa ge	Normal	Steppa ge	Unk	Steppa ge	Steppa ge	Steppag e
Muscle atrophy	Dist LL L>R	Distal LL (calf hypertr ophy)	Calves down	Dist LL	Calves down	Feet	Feet	Calves down	None	Calves down	Dist LL	Unk	Unk	Dist LL	Hands and dist LL	Dist UL and LL	Unk	Dist LL R>L	Dist LL	Dist LL > UL
Neurophys iology	Limited study: LL motor only. Asymm etric LD motor neurop athy	*Axona l and demyel inating neurop athy (mainly axonal) bilatera lly, L>R	LD motor neurop athy with signific ant conduc tion slowing and block	LD MP axonal neurop athy	MP LL predo minant axonal neurop athy	MP LL predo minant axonal neurop athy with some conduc tion slowing	*Mixed axonal and demyel inating neurop athy (mainly axonal) UL and LL	LD MP axonal neurop athy with upper limb asymm etry	Very limited study; LD sensor y and motor neurop athy	LD axonal neurop athy, some acute EMG change S	LD MP axonal neurop athy with conduc tion slowing	Not perfor med	Very limited only single nerve studied	*motor axonal neurop athy	LD MP demyel inating neurop athy	Limited study; MPLD neurop athy	*Mixed motor> sensor y neurop athy (axonal >demy elinatin g) involvi ng both LL, R>L	**Mot or neurop athy with conduc tion slowing	LD MP axonal neurop athy with minima I conduc tion slowing	*Axonal motor neuropa thy

Table 1. Clinical features of *ARHGAP19* individuals. MP motor predominant * neurophysiology data not seen +/- report available only ** very limited study, Clinical sensory involvement refers to symptoms and/or signs. Δ assessed approximately 2 years after onset of acute left hand weakness. CS conduction slowing LL lower limb UL upper limb KJ knee jerk, AJ ankle jerk, SG increased sandal gap, MRC grade ADF/APF = medical research council power grading of power in ankle dorsiflexion/ankle plantar flexion. ~= approximate (where known). If there is discrepancy between limbs, a comma separates right and left. > greater than, LD length-dependent , M male, F female, Unk unknown, dist distal, prox proximal.